Patent Grant
11827989
The present disclosure relates to systems and methods for generating nitric oxide, and more particularly to the use of the generated nitric oxide for the prevention and/or treatment of infections, including microbial infections, fungal infections, bacterial infections and viral infections, including but not limited to COVID-19.
Low-dose inhaled nitric oxide treatment has been in practice for decades. Nitric oxide relaxes smooth muscle in the walls of pulmonary blood vessels, thereby decreasing the load on the right heart, decreasing pulmonary vascular resistance and increasing blood oxygen levels. Nitric oxide has also been shown to have viricidal and bactericidal effects. NO concentration within the nasal cavity of healthy volunteers has been measured to be 2 ppm, suggesting that low amounts of NO can be sufficient to stave off infection. In some applications, disinfection treatment is done at higher doses, 200 to 300 ppm NO for example, which has the potential of being faster-acting. For reference, typical inhaled NO concentrations to improve blood oxygenation are in the range of 1-80 ppm.
The objective of disinfection via NO is to dose the entire lung with sufficient concentration of NO to disinfect. In some applications, a minimum concentration of 150 ppm is applied for viricidal effect. In some applications, inhaled NO concentrations can be about 300 ppm, about 500 ppm, about 700 ppm, about 900 ppm, about 1100 ppm, or about 1300 ppm.
In some applications, inhaled NO concentrations reach as high as 1350 ppm. In some applications, inhaled NO concentrations range from 150 ppm to 1350 ppm, 200 ppm to 600 ppm, 300 ppm to 1200 ppm, 400 ppm to 1000 ppm, or 150 ppm to 1000 ppm.
NO changes the viscosity of mucous, improving the ability to clear gas pathways. In addition, NO changes the chemical properties of mucous, making it less hospitable for microbes. In addition, NO2 is water soluble and makes mucous more acidic which can deter/kill microbes.
Bacteria form a biofilm to protect themselves (i.e. a lipid boundary layer). Antibiotics are unable to pass through biofilms. Some drugs require entry into the bacteria so that their physiology can be altered leading to cell death. There are two strategies to gaining access for antibiotics to bacteria that are protected by a biofilm: 1) chemical break down the biofilm and 2) mechanical removal of biofilm. Both of these approaches can make drug-resistant bacteria susceptible to antibiotics. NO helps this process in three ways: 1) breaking down the biofilm chemically due to its lipophilic properties, 2) loosening mucus to facilitate mucous removal, and 3) acting directly on the bacteria to exact nitrosative and oxidative damage.
NO treatment can be done with tanks, however tanks are filled with high concentration NO gas (800 ppm typically) that gets diluted down to therapeutic concentration levels. It follows that tanks will last less time when higher concentrations of NO (less dilution) are delivered, because a tank begins with a finite number of NO molecules present. A further concern is that NO tanks are filled with a balance of N2 (99.92%). Higher doses of NO result in higher levels of N2 which can significantly decrease the inspired oxygen levels. As an example, a dose of 80 ppm from a tank of 800 ppm will dilute the inspired oxygen level by 10%. Since there is no oxygen in the tank NO, inspired oxygen decreases 10% from a typical atmospheric level of 21% to less than 19%. A dose of 160 ppm NO from an 800 ppm tank would dilute the inspired gas 20%, bringing inspired oxygen levels to roughly 17%. In many cases, supplemental oxygen is required in addition to tank NO to ensure adequate oxygen supply to a patient. This adds complexity and expense to a NO treatment. Thus, it is beneficial to have a system that is not limited by the volume and concentration of a tank, does not dilute atmospheric oxygen levels, and can generate NO on demand at the patient bedside.
The present disclosure relates to systems, devices, and methods for nitric oxide generation for use with various ventilation and/or medical devices for the prevention and/or treatment of microbial infections, fungal infections, bacterial infections, viral infections, SARS, COVID-19, and other respiratory diseases and disorders. The systems and methods disclosed herein can be used to protect patients, caregivers, and the environment.
In some embodiments, a system for providing nitric oxide can include at least one pair of electrodes configured to generate a product gas containing nitric oxide from a flow of a reactant gas, and at least one controller configured to regulate an amount of nitric oxide in the product gas generated by the at least one pair of electrodes using one or more parameters as an input to the controller. One or more sensors are configured to collect information relating to at least one of patient information, the reactant gas, the product gas, and an inspiratory gas into which at least a portion of the product gas flows, the sensors configured to communicate the information to the controller to be used as the one or more parameters. The patient information includes information relating to a methemoglobin (MetHg) measurement collected from a MetHg sensor.
In some embodiments, the MetHg measurement from the MetHg sensor is used by the controller to generate an amount of the product gas based on at least one of a threshold MetHg level and a rate of change of the MetHg measurement. In some embodiments, the MetHg threshold level can be maintained by the controller for a predetermined time. In some embodiments, the MetHg measurement from the MetHg sensor is monitored by the controller such that the Methg measurement is maintained at less than the threshold MetHg level until a predetermined mass of NO has been delivered to the inspiratory gas.
In some embodiments, the MetHg measurement from the MetHg sensor is used by the controller to deliver an amount of the product gas based on at least one of a threshold MetHg measurement and a rate of change of the MetHg measurement. In some embodiments, a MetHg threshold level is maintained by the controller for a predetermined time. In some embodiments, the MetHg measurement from the MetHg sensor is monitored by the controller such that the Methg measurement is maintained at less than a threshold MetHg level until a predetermined mass of NO has been delivered to the inspiratory gas.
In some embodiments, the MetHg sensor is integrated into the system. In some embodiments, the controller is configured to dynamically change a NO dose using the MetHg measurement from the MetHg sensor to keep the MetHg measurement below a threshold while maximizing quantity of NO delivered. In some embodiments, the controller is configured to require an initial measurement from the MetHg sensor before NO delivery begins.
In some embodiments, the controller is configured to suspend NO generation based on the information from the MetHg sensor. In some embodiments, the controller is configured to resume NO generation when the MetHg measurement from the MetHg sensor decreases to a threshold level.
In some embodiments, the system can also include an injection pump configured to deliver methylene blue to a patient and in communication with the controller, the controller configured to control a delivery of the methylene blue to decrease a MetHg level.
In some embodiments, the controller is configured to vary a mass of NO delivered within each breath of the inspiratory gas from zero to a predetermined maximum value to deliver a target mass of NO per unit time. In some embodiments, a concentration of NO in the product gas is at least 150 ppm.
A method of generating nitric oxide (NO) can also be provided, and can include ionizing a reactant gas using at least one pair of electrodes to generate a plasma for producing a product gas containing nitric oxide within a flow comprising a reactant gas, and controlling an amount of nitric oxide in the product gas using one or more parameters as input to a control algorithm used by one or more controllers to control the electrodes, at least one of the one or more parameters being related to at least one of patient information, the reactant gas, the product gas, and an inspiratory gas into which at least a portion of the product gas flows. At least one of the parameters related to patient information is in the form of a methemoglobin (MetHg) measurement from a MetHg sensor such that the MetHg measurement is used by the controller to control the amount of nitric oxide delivered to a patient.
In some embodiments, controlling the amount of nitric oxide delivered to the patient includes the controller using a predetermined threshold MetHg level. In some embodiments, the controller monitors the MetHg measurement such that MetHg measurement remains below the predetermined MetHg threshold level. In some embodiments, the controller delivers a predetermined mass of NO to the inspiratory gas. In some embodiments, a MetHg level is maintained below the predetermined MetHg level until a predetermined mass of NO has been delivered to a portion of the inspiratory gas that is inhaled by a patient. In some embodiments, the controller is configured to vary a mass of NO delivered within each breath of the inspiratory gas to deliver a target mass of NO per unit time. In some embodiments, a concentration of NO in the product gas is at least 150 ppm.
The present disclosure is further described in the detailed description which follows, in reference to the noted plurality of drawings by way of non-limiting examples of exemplary embodiments, in which like reference numerals represent similar parts throughout the several views of the drawings, and wherein:
While the above-identified drawings set forth presently disclosed embodiments, other embodiments are also contemplated, as noted in the discussion. This disclosure presents illustrative embodiments by way of representation and not limitation. Numerous other modifications and embodiments can be devised by those skilled in the art which fall within the scope and spirit of the principles of the presently disclosed embodiments.
The following description provides exemplary embodiments only, and is not intended to limit the scope, applicability, or configuration of the disclosure. Rather, the following description of the exemplary embodiments will provide those skilled in the art with an enabling description for implementing one or more exemplary embodiments. It will be understood that various changes may be made in the function and arrangement of elements without departing from the spirit and scope of the presently disclosed embodiments.
Specific details are given in the following description to provide a thorough understanding of the embodiments. However, it will be understood by one of ordinary skill in the art that the embodiments may be practiced without these specific details. For example, systems, processes, and other elements in the presently disclosed embodiments may be shown as components in block diagram form in order not to obscure the embodiments in unnecessary detail. In other instances, well-known processes, structures, and techniques may be shown without unnecessary detail in order to avoid obscuring the embodiments.
Also, it is noted that individual embodiments may be described as a process which is depicted as a flowchart, a flow diagram, a data flow diagram, a structure diagram, or a block diagram. Although a flowchart may describe the operations as a sequential process, many of the operations can be performed in parallel or concurrently. In addition, the order of the operations may be re-arranged. A process may be terminated when its operations are completed but could have additional steps not discussed or included in a figure. Furthermore, not all operations in any particularly described process may occur in all embodiments. A process may correspond to a method, a function, a procedure, a subroutine, a subprogram, etc. When a process corresponds to a function, its termination corresponds to a return of the function to the calling function or the main function.
Subject matter will now be described more fully with reference to the accompanying drawings, which form a part hereof, and which show, by way of illustration, specific example aspects and embodiments of the present disclosure. Subject matter may, however, be embodied in a variety of different forms and, therefore, covered or claimed subject matter is intended to be construed as not being limited to any example embodiments set forth herein; example embodiments are provided merely to be illustrative. The following detailed description is, therefore, not intended to be taken in a limiting sense.
In general, terminology may be understood at least in part from usage in context. For example, terms, such as “and”, “or”, or “and/or,” as used herein may include a variety of meanings that may depend at least in part upon the context in which such terms are used. Typically, “or” if used to associate a list, such as A, B, or C, is intended to mean A, B, and C, here used in the inclusive sense, as well as A, B, or C, here used in the exclusive sense. In addition, the term “one or more” as used herein, depending at least in part upon context, may be used to describe any feature, structure, or characteristic in a singular sense or may be used to describe combinations of features, structures or characteristics in a plural sense. Similarly, terms, such as “a,” “an,” or “the,” again, may be understood to convey a singular usage or to convey a plural usage, depending at least in part upon context. In addition, the term “based on” may be understood as not necessarily intended to convey an exclusive set of factors and may, instead, allow for existence of additional factors not necessarily expressly described, again, depending at least in part on context. The term “flow” is inclusive of the terms “mass flow” and “standard flow” (i.e. the equivalent flow rate at standard temperature and pressure conditions).
Systems and methods for preventing and/or treating infections with nitric oxide (NO) are disclosed including systems, devices and methods for the generation, delivery and monitoring of nitric oxide to patients. Methods of delivering effective and controlled doses of nitric oxide are described. Applications including antimicrobial treatments are described for prophylactic applications to individuals and healthcare workers, as well as treatment of infected patients. Various treatment delivery methods and dosing strategies are described as well as a remote gas monitor device that can be mounted at or near the point of inspiration.
The presently disclosed embodiments can be used to prevent and/or treat infections, including microbial infections, fungal infections, bacterial infections and viral infections. The presently disclosed embodiments can be can be used to prevent and/or treat various respiratory ailments, disorders and diseases including, but not limited to, viruses, COVID-19, coronavirus, influenza, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), upper airway infections (i.e., sinusitis, stomatitis, etc.), lung infections (i.e., bronchitis, bronchiolitis, pneumonia, etc.), cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) or chronic obstructive lung disease (COLD), nontuberculous mycobacteria (NTM) or labored breathing, challenged breathing or any breathing difficulty It can also be used to treat blood prior to transfusion to bind with hemolyzed blood and prevent renal injury and hypertension.
The present disclosure relates to systems and methods of nitric oxide (NO) delivery for use in various applications, for example, inside a hospital room, in an emergency room, in a doctor's office, in a clinic, in an ambulance, in a patient transport helicopter, in the battlefield, in a patient transport fixed wing plane, in a ship hospital, nursing home, at home, and outside a hospital setting as a portable or ambulatory device. A NO generation and/or delivery system can take many forms, including but not limited to a device configured to work with an existing medical device that utilizes a product gas, a stand-alone (ambulatory) device, a module that can be integrated with an existing medical device, one or more types of cartridges that can perform various functions of the NO system, an electronic inhaler, and an electronic NO tank. The NO generation system uses a reactant gas containing nitrogen and oxygen, including but not limited to ambient air, to produce a product gas that is enriched with NO. In some embodiments, house compressed air from either a compressor or a cylinder is used. In some embodiments, a combination of one or more of house oxygen, house nitrogen, house air and ambient air are used as reactant gas. The NO generation device can include batteries, power supplies, connectors to receive external DC power, connectors to receive external AC power, a user interface, speaker, microphone, alarms, graphical display, carrying case, replaceable scrubber(s), replaceable filter(s), and other features that enable portability and use in the field.
A NO generation device can be used with any device that can utilize NO, including but not limited to a ventilator, an anesthesia device, house air compressor, a defibrillator, a ventricular assist device (VAD), a Continuous Positive Airway Pressure (CPAP) machine, a Bilevel Positive Airway Pressure (BiPAP) machine, a non-invasive positive pressure ventilator (NIPPV), high flow oxygen, a nasal cannula application, a nebulizer, an extracorporeal membrane oxygenation (ECMO), a bypass system, an automated CPR system, an oxygen delivery system, an oxygen concentrator, an oxygen generation system, and an automated external defibrillator AED, MRI, a humidifier, and a patient monitor. In addition, the destination for nitric oxide produced can be any type of delivery device associated with any medical device, including but not limited to a nasal cannula, a manual ventilation device, a face mask, inhaler, endotracheal tube, SCOOP catheter, or any other delivery circuit. The NO generation capabilities can be integrated into any of these devices, or the devices can be used with a NO generation device as described herein. For instance, a mask could contain a NO generator within it to facilitate continuous sterilization of inspired air.
Infected patients are administered NO with a variety of methods, including but not limited to a ventilator, CPAP, a face mask, and a breathing mouthpiece. In some embodiments, gas passing through the NO device is propelled by a patient's inspiratory effort (self-breathing). In some embodiments, for example patients receive continuous high flow therapy (e.g. 8 lpm for neonates and 70 lpm for adults) with either air or 02-enriched air as the carrier gas.
As with conventional NO therapy, nitrogen dioxide (NO2), the result of nitric oxide oxidation, is monitored to ensure safe levels. Nitrogen dioxide is water soluble, forming nitric acid when it enters water. Acceptable limits of NO2 are dependent on the exposure time. For example, at one time, the OSHA limit for an 8-hour workday was 5 ppm of NO2. It follows that high dose NO treatments lasting 8 hours should stay below 5 ppm NO2 and the lower the NO2 level, the better. NO2 levels greater than 5 ppm at shorter durations may be clinically relevant if supported by a clinical risk/benefit analysis. It will be understood that the NO2 limit can vary. Selection of an acceptable NO2 limit can be a function of one or more of the following parameters: NO dose, patient condition, criticality of NO therapy, duration of treatment, fraction of breaths dosed, inhaled oxygen levels, breath rate, and scrubber type.
Various features of a high dose NO generation and delivery device can decrease the level of NO2 within the product gas. For example, soda lime scrubbers can be located within the NO generation device and/or in other locations between the device and the patient to absorb NO2 such as a delivery tube, humidifier, mask, inspiratory limb, etc. Since NO2 is formed by the oxidation of NO, the transit time from the plasma chamber to the patient can be minimized, thereby minimizing the time that NO can oxidize.
The NO oxidation rate is proportional to the square of the NO concentration. Another approach to reducing inhaled NO2 levels is to dilute high concentration product gas exiting the plasma chamber of a NO generation device as soon as possible to benefit from the fact that NO oxidation rate is proportional to gas pressure. Soda lime is comprised of one or more alkaline materials including one or more of sodium hydroxide, calcium hydroxide and potassium hydroxide. It should be understood a scrubber is not limited to soda lime scrubbers, and that various NO2-selective scrubbing materials can be used, including but not limited to ascorbic acid, 4-Hydroxy-TEMPO, and TEMPOL (formally 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl, a heterocyclic compound).
System Overview
The plasma chamber 22 includes one or more electrodes 24 therein that are configured to produce, with the use of a plasma generation circuit 28 (such as a microwave circuit), a product gas 32 containing a desired amount of NO from the reactant gas. The system includes a controller 30 in electrical communication with the plasma generation circuit 28 and the electrode(s) 24 that is configured to control the concentration of NO in the product gas 32 using one or more control parameters relating to conditions within the system and/or conditions relating to a separate device for delivering the product gas to a patient and/or conditions relating to the patient receiving the product gas. In some embodiments, the plasma generation circuit is a high voltage circuit that generates a potential difference across an electrode gap. In some embodiments, the plasma generation circuit is a radio frequency (RF) power generation circuit delivering RF power to one or more RF electrodes. In some embodiments, the RF power operates around 13.56 MHz with power in the 50-100 W range, however other power ranges can be effective depending on electrode design, production targets and reactant gas conditions. In some embodiments, RF power operates around 2.45 GHz for improved coupling and excitation of N2 molecules. The controller 30 is also in communication with a user interface 26 that enables a user to interact with the system, view information about the system and NO production, and control parameters related to NO production.
In some embodiments, the NO system pneumatic path includes a pump pushing air through a manifold 36. The manifold is configured with one or more valves; three-way valves, binary valves, check valves, mass flow controllers, and/or proportional orifices. The treatment controller 30 controls the flow of the pump, the power in the plasma and the direction of the gas flow post-electrical discharge. By configuring valves within the manifold (not shown), the treatment controller 30 can direct gas to the manual respiration pathway, the ventilator pathway or the gas sensor chamber for direct measurement of NO, NO2 and O2 levels in the product gas. In some embodiments, respiratory gas (i.e. treatment flow) is directed through an inspiratory flow cartridge that measures the flow of the respiratory gas and merges the respiratory gas with NO product gas.
The output from the NO generation system in the form of the product gas 32 enriched with the NO produced in the plasma chamber 22 can either be directed to a respiratory or other device for delivery to a patient, or can be directed to a plurality of components provided for self-test or calibration of the NO generation system. In some embodiments, the system collects gases to sample in two ways: 1) gases are collected from a patient inspiratory circuit near the patient and pass through a sample line 48, a filter 50, and a water trap 52, or 2) gases are measured directly from the pneumatic circuit as they exit the plasma chamber 22. In some embodiments, product gases are shunted with a shunt valve 44 to the gas sensors after being scrubbed but before dilution into a patient airstream. Shunting of flow of product gas to the gas sensors may consist of the entire product gas flow or a portion of the product gas flow. In some embodiments, the gas sensors measure NO and/or NO2 in the primary flow of product gas from the plasma chamber (no shunting) to enable continuous flow to the patient. In some embodiments, product gases are collected from an inspiratory air stream near the device and/or within the device post-dilution. Within the gas analysis portion of the device, the product gas passes through one or more sensors to measure one or more of temperature, humidity, concentrations, pressure, and flow rate of various gasses therein.
The reactant gas 62 is converted into product gas 82 when it passes through the plasma chamber 72 and is partially converted into nitric oxide and nitrogen dioxide. An altitude compensator 84, typically consisting of one or more valves (for example, proportional, binary, 3-way), is optionally used to provide a back-pressure within the plasma chamber 72 for additional controls in nitric oxide production. Product gases pass through a manifold 86, as needed, to reach a filter-scrubber-filter 88 assembly that removes nitrogen dioxide from the product gas. From the filter-scrubber-filter 88, product gas is introduced to a patient treatment flow directly, or indirectly through a treatment flow cartridge 90. In some embodiments, the treatment flow cartridge 90 includes a sensor 92 that measures the treatment flow 93. The treatment flow measurements from the sensor 92 serve as an input into the reactant gas flow controller 70 via the treatment controller 80. The sensor 92 measures one or more properties of the treatment gas from the following list: flow rate, pressure, water content/humidity, and oxygen level. After product gas 82 is introduced to the treatment flow, it passes through inspiratory tubing. In the treatment flow line, a fitting 96 is used to pull a fraction of inspired gas from the inspiratory flow, through a sample line 98, filter 100, water trap 102 and Nafion tubing to prepare the gas sample and convey it to gas sensors 104. Sample gas exits the gas analysis sensor pack 104 to ambient air. In some embodiments, sample gas is scrubbed for NO/NO2 prior to release to atmosphere (not shown). In some embodiments, the system 60 can optionally direct gas through a shunt valve 94 and shunt gas path 95 directly to the gas sensor pack and out of the system. In some embodiments involving the shunt valve 94, the manifold 86 includes a valve (not shown) to block flow to the filter-scavenger-filter when the shunt valve 94 is open.
Product gas passes through a pump 120, a NO2 scrubber 122, and a particulate filter 124 prior to arriving at a flow controller 126. In some embodiments, the flow controller is in the form of a simple, binary valve. In some embodiments, the flow controller is in the form of one or more mass flow controllers with flow feedback from a flow and/or pressure sensor. Product gas 128 passes by one or more optional gas sensors 130 that indicate the quantity of NO and/or NO2 in the product gas stream. In some embodiments, this information can be utilized for closed-loop control of NO production. In some embodiments, this information is utilized to detect whether or not the NO2 scrubber is at or near the point of exhaustion. Product gas exits the device and passes through a delivery device 132 to a patient inspiratory gas stream 134.
The NO generator shown in
A treatment controller 136 receives user inputs for patient parameters and dose level. Typically, a software-controlled, electro-mechanical device, the treatment controller utilizes user inputs and sensor inputs to generate plasma and flow control parameters that govern the production and delivery of NO to the patient.
Dose Delivery
Constant Inhaled Concentrations
In some embodiments, the inhaled concentration during disinfecting NO therapy is constant. This can provide an even NO dose throughout the lung of the patient. Constant NO generation and injection into the inspiratory flow produces constant NO concentrations in constant inspiratory flows. The same results occur when NO from a tank is delivered constantly to a constant inspiratory flow. When inspiratory flow is pulsatile, as in ventilator treatments, constant NO production results in variable concentrations of NO within the inspiratory pathway. Periods of high inspiratory flow have lower concentration from the constant flow of NO, and periods of low inspiratory flow have higher concentration. These variations in NO concentration are not necessarily an issue in high dose NO therapy so long as the minimum concentration within the inspired gas is greater than the bactericidal/viricidal/fungicidal concentration required to be therapeutic.
Proportional Flow
In some embodiments, a high-concentration therapy NO generator delivers constant concentration NO to the inspiratory limb in proportion to the inspiratory flow rate, creating a constant concentration of NO in the inspired gas.
Pulsed Flow
In some embodiments, NO is only introduced to the inspiratory flow during periods of inhalation. This approach conserves NO by ensuring that generated NO is delivered to the patient. This efficiency with NO production results in increases in battery life, electrode life, and scrubber life for example. Pulsed NO flow can also allow for NO to be stored within the device, which can provide a longer residence time within the scrubber which can provided a higher level of scrubbing efficiency (percent NO2 removal). Pressurized scrubbers can remove 95 to 100% of the NO2 that enters the scrubber. The scrubber also removes NO2 that forms due to oxidation of NO within the scrubber. Pulsed NO can be delivered near the patient, thereby decreasing the exposure time of high concentration NO to high concentration oxygen, resulting in less NO oxidation.
Mixing Element
In some embodiments, a mixing element is placed within the inspiratory limb to mix NO and inspiratory gas post-NO injection. Similarly, a mixing element can be used to mix oxygen with inspiratory gas and/or NO after introduction of oxygen to the inspiratory gases. In some embodiments, oxygen is introduced to the inspiratory flow at the latest possible point (e.g. ET tube, Patient Wye connector, proximal ventilator tubing, mask, scoop catheter, nasal cannula prong) to minimize oxidation of NO which increases significantly with oxygen concentration.
Face Mask
In some embodiments, NO is delivered to a patient through a face mask. As a patient exhales, exhaled gases can contain levels of NO and NO2 which can collect in the environment. In some embodiments, a face mask includes a NO2 and/or NOx scrubber that scrubs exhaled gases before release from the system. In some embodiments, the NOx scrubber is made one or more materials including one or more of potassium permanganate, activated carbon, soda lime, and TEMPO. In some embodiments, a filter, such as a HEPA filter, is used to filter infectious particles from the exhaled gas from a mask.
Secondary Pump
In some embodiments, the inspiratory flow pressure can exceed the pressure within the NO generation system. In some embodiments, a NO generation system includes a product gas pump that increases the pressure of product gas so that it can flow into a pressurized flow of inspiratory gas. In some embodiments, the pump operates at a constant rate to pressurize product gas. In some embodiments, the product gas pump flow rate varies in relation to the inspiratory flow pressure. In some embodiments, the product gas pump flow rate is proportional to the inspiratory flow rate. In some embodiments, a NO generation system operates at a pressure that is always higher than the inspiratory gas so that product gas can always flow towards the patient.
NO Generation in Inspiratory Flow
Given that a NO generator sources N2 and O2 from the atmosphere, it does not dilute O2 levels in the same way that tank NO can. Tank NO is comprised of NO in a balance of nitrogen. Due to the fixed concentration of NO gas within the tank, increased doses of NO require an increased volume of NO which decreases inspired O2 levels. In contrast, a NO generation device generates NO in a reactant gas flow containing N2 and O2. When additional NO is required, plasma activity can be altered to convert a greater portion of the reactant gas to NO without increasing the amount of reactant gas and altering inspiratory oxygen dilution significantly. As a result, the level of dilution of inspiratory flow from a NO generation device can be lower than that of tank-sourced NO. This can be important for patient treatments where high inspired oxygen concentrations are required. For example, during low dose NO therapy (0 to 80 ppm), it can be important to not dilute the inspiratory flow more than 10% with NO-containing gas. This limit stems from a desire to not dilute 100% O2 cases more than 10% and due to the risk of interfering with concomitant therapies, such as ventilators that may alarm in the presence of excessive changes in gas volume/pressure within the ventilator circuit. For high dose NO treatment, there is not the same limitation to dilution, owing to the fact that 100% O2 is not typically used. Given that 100% O2 is not typically used in high-dose NO treatments, N2 and O2 are present within the inspiratory gas enabling NO to be generated within the entire inspiratory flow in some cases. In some embodiments, NO is generated in a side stream sourced from the inspiratory flow. In some embodiments, ambient air is sourced for NO generation and merged with inspiratory flow. In some embodiments, N2 and O2-containing gas is sourced from a cylinder or hospital air supply. In some embodiments, N2 and/or O2-containing gas is sourced from an oxygen concentrator. The higher the concentration of NO in the NO-containing gas, the lower the level of inspiratory flow dilution is required to achieve a target NO dose. Lower levels of dilution decrease the risk of affecting concomitant therapies. For example, ventilators can accommodate a certain level of difference between output gas and input gas. When a NO device is added to the ventilation circuit, gas volume is added from the NO device and subtracted from the flow for gas sensor measurements. The net volume change to the inspiratory circuit should be minimized to minimize disruption to the ventilator treatment.
Variable Production
When NO is generated and delivered at a constant concentration and flow rate into a dynamic inspiratory flow, the inhaled concentration can vary. For example, this can be the case in a CPAP application where gas flow rate is little to none (slow flow rate) between breaths and then surges as the patient inspires. With constant NO generation and delivery, periods of low inspiratory flow, i.e. between breaths, result in higher NO concentrations than periods of high inspiratory flow rate. The location of the zone of high concentration NO with respect to the patient depends on the length of tubing between injection point and patient. This zone of high concentration can be leveraged to improve overall device efficiency if the system can be designed so that the zone of high concentration NO is the volume of gas that is inspired by the patient. In some embodiments, NO is generated continuously at a low level that sufficiently doses the slow-moving gas between breaths and ensures that the slow moving, accurately dosed gas is inspired. In some embodiments, a NO generator only generates plasma during the slow flow rate between breaths to save energy while ensuring that the slow-moving, accurately dosed gas is inspired. Ensuring that the slow moving, accurately dosed gas is inspired is a function of the slow flow rate and the inspiratory gas volume between the NO injector and the patient. This volume can be comprised of tubing, a bag, a rebreather mask, a humidifier, a gas sample port, fittings and other inspiratory pathway components. These approaches effectively pre-load a lung's worth of air at the correct concentration while running at much lower production rates than would be needed to accurately dose the peak inspiratory flows. It can be used in applications where the volume of gas between the NO generator and the patient is well-controlled.
In some embodiments, a NO device is configured to dose a bias flow with a target NO concentration. The volume of tubing between the NO device and the patient is sized to be as large or greater than the tidal volume of the patient so that the volume of inspired gas comes from bias flow. In this case, the bias flow needs to be of sufficient volumetric flow rate to replace the entire tubing volume between breaths. For example, consider a patient breathing at ten 500 ml breaths per minute at an inspiration to expiration ratio of 1:2. The breath period is 6 seconds (60 seconds/10 bpm). The inspiratory time is 2 seconds and the expiratory time is 4 seconds. The tubing volume should be 500 ml or more so that it can be filled with evenly dosed NO gas. To ensure that the tubing is completely purged between breaths, the bias flow must be sufficiently high. If the tubing volume is 500 ml (1.3 m of a 22 mm ID ventilator tube), for example, the bias flow must be at least 500 ml/4 sec, or 125 ml/sec, or 7.5 lpm. This method eliminates the potential for the patient to breath under-dosed inspiratory gas associated with the inspiratory bolus. As an example, if the patient inhales at a rate of 52.5 lpm, a 7-fold increase in flow rate (52.5/7.5=7), the concentration of gas dosed by the system during inspiration will be 7 times less than the target. Thus, if the NO generation device delivers sufficient NO to dose a constant flow of 7.5 lpm of inspiratory gas, the patient will breath evenly dosed NO despite there being volumes of gas generated during inspiration that are underdosed. The under-dosed gas sweeps by the patient during patient exhalation and the patient inspires accurately dosed gas in phase with the bias flow. This approach works for all respiratory rates, so long as the bias flow is high enough to purge the inspiratory limb between breaths and the volume of the inspiratory limb is as large or greater than the inspiratory volume. Faster respiratory rates, provide less time to purge the gas volume between injector and patient, requiring faster bias flows to purge the gas volume in time. It follows that slower respiratory rates result in greater time to purge the gas volume. In some embodiments, the bias flow is faster than necessary, i.e. it purges the gas volume between NO injector and patient in less time than the duration of exhalation and pause prior to the next inspiration. In this case, a NO device may only introduce NO to the inspiratory limb during the latter part of the bias flow phase so that the gas volume to be inspired is primed with sufficient NO just before patient inhalation.
This concept of being in phase with the bias flow provides a means of NO dose control. If breathing gas accurately dosed during the bias flow provides a maximal level of NO, lower levels of NO can be delivered to the patient by being less in phase. For example, in a system that delivers NO constantly to accurately dose a bias flow, if the inspiratory limb is shortened, the volume of accurately dosed gas that enters the patient will be less, thereby decreasing the delivered dose. In some embodiments, the early portion of a breath can be dosed accurately, and the latter portion of the breath can be dosed at a lesser extent or not at all. In this case, the volume of tubing between NO generator and patient can have less volume than the tidal volume because later portions of the breath will be supplied by gas that was flowing faster than the bias flow at the point of injection and will have lower concentration.
Zero Bias Flow
In some patient treatments, there is little to no flow past the NO device between breaths. This is the case with some ventilators and CPAP machines as well as when a patient is providing the inspiratory flow themselves. For example, a NO device can deliver NO into an inspiratory limb during a period of zero bias flow (patient exhalation) at the target inhaled concentration thereby filling the inspiratory volume with an accurate number of moles of NO. When the patient inhales, the inspiratory volume enters the patient, delivering the entire bolus of NO to the patient when the inspiratory limb volume is less than the inspired volume. Positioning of the NO bolus within the inspiratory limb and coordination with the inspiratory flow device is important for accurate and reliable patient dosing with this approach. Benefits of this approach include reducing the total amount of NO required to be generated, owing to the accurate and complete delivery of the NO. This reduction in NO generation enables increases in battery life, electrode service life and scrubber service life.
Dose Accuracy
Acceptable Concentrations
As mentioned earlier, significant variations in NO concentration can be deemed acceptable for disinfection treatment so long as the minimum inhaled NO concentration is therapeutic. For example, fluctuations of about 150 ppm to 300 ppm during the inspiratory cycle have been deemed acceptable in some cases. In other examples, fluctuations of about 150 ppm to 1350 ppm NO have been deemed acceptable. Acceptance of fluctuations can depend on many factors, including the duration of treatment, and/or susceptibility of the target microbe to NO concentration. When inspiratory flows are variable, it is important to standardize the therapy, parameters, and dosing vernacular related to it. In some embodiments, the minimum NO concentration level of a dynamic inspiratory NO concentration is specified for a therapy. In some embodiments, the average inspiratory NO concentration of a dynamic NO concentration is specified. One or more of Root Mean Square (RMS) average NO production rate, arithmetic mean NO production rate, max NO inspiratory concentration, standard deviation of inspiratory NO concentration and other related factors have also been utilized to specify and/or characterize a NO treatment dose. In some embodiments, a NO delivery device is configured to deliver NO at a particular concentration or mass per breath to a total number of breaths (e.g. 100 breaths). In this case, the system monitors patient breathing directly (sensors on the patient or in the patient flow) or indirectly (from sensors or concomitant therapy devices) in order to count breaths. In some embodiments, a NO delivery device is configured to deliver a number of moles of NO molecules or a mass of NO within a period of time (e.g. x moles in y hours). The moles of NO are delivered within a target range of concentrations (e.g. >minimum lethal concentration for specific pathogen and <concentration that could be harmful to the patient). In some embodiments, a fixed quantity of NO molecules and/or concentration can be delivered in a specific number of breaths over a specified time (e.g. 400 ppm gas in 50 breaths within a 1-hour time period). In this approach, a system may dose a subset of breaths within the treatment window (e.g. 1 hour) instead of dosing every breath. One benefit of this approach is that the system can track a dosing run rate and does not have to accurately detect every breath in order to comply). This approach of limiting the amount of NO delivered over a period of time is a means to mitigate against the potential of methemoglobinemia while ensuring that sufficient dose is also delivered to treat a particular clinical condition (e.g. respiratory infection).
Dose Smoothing
In some embodiments, a variable reservoir is placed within the inspiratory limb to collect inspiratory flow between breaths and homogenize the NO concentration. The reservoir can be positioned in any location between the point of NO injection and the patient's nose/mouth, including but not limited to the inspiratory limb, a non-rebreather mask, or face mask. In some embodiments, NO delivery is constant into a variable flow inspiratory stream. Gas collects within the variable reservoir and mixes between breaths. As the patient breaths, the reservoir empties. Filling and emptying of the reservoir can be passive, active, or both. The inspiratory flow rate is set at or near the patient minute volume so that the reservoir does not over-fill or gradually become empty. In some passive embodiments, the reservoir is an elastomeric balloon, i.e. one made from a material that stretches (latex, silicone, rubber for example). In some passive embodiments, the reservoir is a rigid balloon, i.e. balloon made from a non-elastic material but still flexible (mylar, polyethylene, for example). In some active embodiments, a piston or bellows is actuated to fill and empty out of phase with the patient inspiratory cycle. Actuation of the piston or bellows can be achieved any number of ways, including but not limited to linear motor, motor-driven rack and pinion, crank-rocker mechanisms, balloon displacement in a rigid container, and other embodiments. This variable reservoir approach can attenuate the NO concentration fluctuations associated with constant NO delivery into a variable inspiratory flow by providing a volume and time for NO gas and inspiratory gas to mix.
In some embodiments, a scrubber is located between the variable reservoir and the patient to remove NO2 that can form during residence within the bag. In some embodiments, the variable reservoir is at least partially filled with a scrubber material. In some embodiments, the variable reservoir is at least partially filled with an open-cell foam that is either constructed from or coated with a NO2-scrubbing material.
Dose Ramping
Odors have an absolute threshold of detection and a difference threshold. The absolute odor threshold is the lowest concentration perceptible by the human nose. For NO, the absolute odor threshold is 0.3 to 1 ppm. For NO2, the absolute odor threshold is 0.1 to 0.4 ppm. The difference threshold is the amount that a value needs to change before a person will recognize that change 50% of the time.
High concentrations of NO can be smelled by a patient and can be irritating. In some embodiments of NO treatment, the dose is gradually increased during a treatment session with increments in concentration that are less than the difference threshold. Gradual increases in NO decrease the ability of a patient to perceive high concentrations of NO thereby improving a patient's tolerance to treatment. Gradual increases in NO can also enable a person that is very sensitive to odors to receive NO treatment at all. This approach can also enable a patient to tolerate a longer treatment with NO, notwithstanding methemoglobin limitations. Similarly, NO concentration can be decreased from a maximal level in slow decrements that are imperceptible to the patient. In some embodiments, slow dose changes are utilized in clinical trials to decrease a patient's ability to perceive NO treatment, effectively blinding them in the study.
Dose Decreases
In some embodiments, the initial NO dose is at its maximum at or near the beginning of treatment. The patient is able to accommodate high doses of NO at this time because methemoglobin levels are low. As treatment continues, NO dose can be automatically decreased according to a treatment schedule and/or changes in methemoglobin level. This can prolong exposure to the NO for as long as possible, maximizing the antimicrobial efficacy of the treatment while maintaining patient safety.
Dose Balanced in Nitrogen
In some embodiments, NO is delivered in a balance of nitrogen to infected parts of the lung or to the entire lung. This can only be done in a subset of breaths to avoid hypoxemia, however it can provide higher doses of NO to the lung tissue to fight infection while practically eliminating the risk of NO2 delivery. In an exemplary treatment, a patient breathes normally and receives a breath of 800 ppm NO balanced with N2 every 10th breath for 10 minutes. In another embodiment, the patient receives a breath of 200 ppm NO balanced with N2 every minute for 15 minutes.
Prophylactic Prevention of Methemoglobinemia
Methemoglobinemia forms when nitric oxide oxides iron in heme to increase its affinity for oxygen. This results in reduced release of oxygen to tissues. Lethal levels of methemoglobin (MetHg) are 25%, however levels seldom exceed 10% in the clinic. Methemoglobinemia is treated with intravenous doses of a methemoglobin medication, such as methylene blue, ascorbic acid and riboflavin. In the case of a lung infection, the risk of methemoglobinemia must be balanced with the benefit of eliminating the infection. In some embodiments, a methemoglobin medication, such as methylene blue, is administered (e.g. 1-2 mg/kg body weight) to a patient prophylactically prior to and/or during nitric oxide treatment to prevent the onset of methemoglobinemia and enable higher doses of NO to be delivered to the infected lung and airway tissue.
The NO generation and/or delivery device can use a proportional integral derivative (PID) control scheme based on the MetHg measurement to vary NO injection to maintain MetHg below a threshold. In some embodiments, the NO generation and/or delivery device monitors the rate of change (i.e., the slope) of MetHg and adjusts the NO injection accordingly to prevent exceeding a threshold. For example, as the rate of change of the MetHg increase such that the MetHg level is rising at a faster rate, the controller of the NO system can slow down the NO injection or stop the generation of NO until the MetHg falls to an acceptable level or the rate of change of MetHg reaches an acceptable rate. In some embodiments, the NO generation/delivery system can also alarm in the event that indicated MetHg levels exceed a threshold.
In some embodiments, as shown in
Treatment Control
Treatment Duration
In some embodiments, a user sets the duration of a NO treatment at the onset of treatment. The duration can be set using a variety of mechanisms, such as by a twisting the rotary knob of an analog timer, setting a digital timer, or selecting a treatment duration from a graphical user interface, for example. In some embodiments, there is a separate start button that initiates treatment. In some embodiments, when the treatment timer runs out, treatment can stop automatically. In some embodiments, an alarm is sounded at the end of the treatment timer and the treatment can stop manually, such as a user shutting down the treatment. In some embodiments, the NO generation system displays time remaining for the treatment.
Treatment End Point
In some embodiments, a NO generation device measures methemoglobin with a sensor or receives a patient methemoglobin measurement from an external device. As high dose NO is delivered, methemoglobin levels can rise. In some embodiments, when methemoglobin levels reach a threshold (e.g. 5%), a NO generation and/or delivery device can respond in one or more of the following ways: stop treatment, generate an alarm, lower the NO dose, and/or pause NO delivery until methemoglobin levels reduce below a second threshold. In some embodiments, the NO dose ramps and ramping ceases when methemoglobin levels reach a particular threshold and NO treatment continues at a constant concentration. In some embodiments, a NO generator displays a methemoglobin measurement on the user interface to inform the user. While the methemoglobin threshold can vary, in some embodiments, a methemoglobin threshold is between 1 and 7%. In some embodiments, resumption of treatment begins when methemoglobin levels drop below 2%. In some embodiments, the methemoglobin level and/or SpO2 level are utilized as inputs into a closed-loop control scheme whereby the NO dose level is varied to do one or more of the following: maximize SpO2, minimize methemoglobin levels, keep methemoglobin levels below a threshold.
Modes of Operation
NO Tank Mode
In some embodiments, a user selects a NO concentration and NO product gas flow rate and the system generates NO gas accordingly, independent of the patient treatment, relying on the user to set the device accurately and route the NO to the patient with appropriate levels of dilution, as applicable. This approach is equivalent to the NO generation device operating like a custom-concentration tank of NO with variable output flow rate.
Manual Mode
In some embodiments, a NO generation system operates in a manual mode, where the user enters the inspiratory flow rate and the desired NO dose, and the NO system produces the desired amount of NO. In some embodiments, the patient minute volume is entered as a value between 5 and 20 lpm in increments of 1-2 lpm. In some embodiments, the target NO level varies from 0.5 to 300 ppm NO. In some embodiments, the inspiratory flow rate is entered by one or more inputs for oxygen flow, air flow and other inspiratory flows. In some embodiments, the NO generation device determines the level of NO production required based on one or more user inputs, such as target NO dose, O2 flow rate, and inspiratory flow rate. This approach provides a user with more controls than other modes and can provide perfect NO concentration dosing when used with an inline reservoir, such as a non-rebreather mask. NO generation is based on user inputs, however, resulting in shifts up or down in inhaled NO concentration related to high or low minute volume estimates provided by the user, respectively. When used in the absence of an inline reservoir for a variable flow treatment, such as CPAP or a ventilator, this approach can result in variable NO concentration over time within the inspiratory limb. NO variations can be acceptable when the minimum inhaled NO concentration is still effective. NO variations can also be acceptable when the system has been designed and deployed to prevent the patient from inhaling under-dosed gas that results from peak inspiratory flows.
Automatic Mode
In some embodiments, a NO generation system measures the inspiratory flow rate and calculates the NO concentration and flow rate required to sufficiently dose the patient. In some embodiments, the NO generation system measures the inspiratory flow and the oxygen flow separately and calculates the NO concentration and flow rate required to sufficiently dose the patient. In some embodiments, a NO generation system measures the inspiratory flow and the user manually enters the oxygen flow and the device calculates the NO product rate required. These approaches result in similar NO concentration variations as manual mode but can reduce or eliminate the risk of erroneous user input for the patient minute volume. When used with an inspiratory line reservoir, such as a rebreather mask, this approach can deliver perfect NO dosing due to the accurate overall NO generation and mixing within the bag. One implementation detail of an inspiratory line reservoir approach is that the gas flow supplying the bag and the patient minute volume need to balance to prevent the reservoir from gradually increasing or decreasing over time due to mismatch in input flow and output flow. In one embodiment, an inspiratory line reservoir is purposely filled to beyond an expected patient tidal volume before a breath to ensure sufficient gas for inhalation. In that same embodiment, the inspiratory line reservoir is emptied to a consistent volume after patient inhalation and before reservoir filling to ensure a consistent datum for filling with each breath. In some embodiments, that datum is a volume of zero ml of gas within the reservoir. In some embodiments, excess gas that is removed from the reservoir in this way is scrubbed prior to release to atmosphere to remove NO and NO2 from the gas.
External Input Mode
In some embodiments, a NO generator receives patient inspiratory flow information from a separate treatment device, such as a ventilator or CPAP machine and generates NO in sufficient quantity to maintain a user-selected inspired NO concentration. Flow information can include many parameters related to the inspiratory flow, bias flow, including inspiratory pressure, oxygen levels, flow rates, and breath timing information.
Fixed Production Device
In some embodiments, a NO generation system is designed to deliver a specific concentration of NO at a specific flow rate (i.e. fixed NO production). This solution can be useful in its simplicity and treatment consistency. In some embodiments, a NO generation system is configured to generate a constant quantity of NO, leaving the responsibility of diluting the NO to inhaled concentrations to the user.
Fixed Inhaled Concentration Device
In some embodiments, a NO generation system is designed to deliver an appropriate amount of NO to achieve a single inhaled NO concentration at a range of flow rates. In some embodiments, the concentration of NO product gas is held constant and the flow rate of product gas entering the inspiratory flow varies proportionally with the inspiratory flow. This results in constant dilution ratio (merged inspiratory flow+NO product gas flow:NO product gas flow). It follows that the NO product gas concentration is equal to the mathematical product of the dilution ratio and the target inhaled concentration. This approach results in tighter inhaled concentration control which can be advantageous when a particular narrow range of NO concentrations are considered therapeutic and/or safe and results in greater treatment to treatment consistency. As the target inhaled NO concentration increases, it gets closer to the NO concentration safety limit, narrowing the acceptable range of NO concentrations and requiring tighter concentration control for safety.
Bias Flow Dosing Device
In some embodiments, a NO generation device generates NO at a constant rate sufficient to accurately dose the bias flow during a patient inspiratory cycle. In some embodiments, the bias flow rate is entered by the user. In some embodiments, the bias flow rate is measured by the NO generation device. In some embodiments, the bias flow rate is provided by an external device.
NO is generated to accurately dose the bias flow with the understanding that inspiratory peak flows will be underdosed.
In some embodiments, the delivered patient dose can be varied intentionally by varying one or more of the length of the inspiratory limb and the flow rate in the inspiratory limb to change the phase relationship between inspiration and the timing of the low concentration volume of gas within the inspiratory limb.
In some embodiments, users of a NO generation and/or delivery device can treat themselves with nitric oxide. In one example, a caregiver can prophylactically self-treat with nitric oxide prior to leaving home in the morning and when they return home in the evening. In one embodiment, NO is either delivered to or generated by a face mask that the User wears during treatment. In some embodiments, NO is generated in air that the patient inhales through a tube, like an inhaler. In some embodiments, the NO generation and/or delivery device has an alarm that reminds the user when it is time to treat. A NO generation and/or delivery device can include wireless and wired connectivity to external devices and the Cloud for monitoring device function, monitoring device use, reminding the user to use the device, providing the user with data related to the treatments and other information. In some embodiments, the NO generation device reports to researchers the level of device use during a clinical trial to enable an assessment of patient compliance with a clinical protocol.
It should be clear that the invention is not limited to the modes of operation listed above and that some embodiments comprise combinations of these concepts.
Nitric Oxide Mask
Design
In some embodiments, it can be important for health care providers to be able to sterilize the air that they inhale. This can protect the user from airborne infectious microbes. A mask can also be used to filter exhaled gas for the safety of nearby people.
Various concentrations of inhaled NO can be used to prevent microbial infection. In some embodiments, the use of inhaled NO at concentrations ranging from about 100 ppb to 159 ppm can be used to prevent infection with microbes including viruses, bacteria, fungi, and mycobacteria. In some embodiments, inhaled concentrations up to 300 ppm may be delivered for short exposures. In some embodiments, inhaled concentrations in ranges from about 50 ppm-155 ppm, 50 ppm-200 ppm, 50 ppm-300 ppm may be delivered. In some embodiments, inhaled concentrations exceeding 300 ppm are delivered every nth breath to expose infectious materials to high doses while minimizing the risk of methemoglobinemia.
In some embodiments, the inhaled NO prevents infection or reduces the infective dose of the microbe resulting in a milder illness.
The users of the inhaled NO can include a variety of users, such as health care professionals (e.g. physicians, and nurses), or other professionals or individuals at risk for infections (e.g. family members of an infected host).
The inhaled NO can be administered in a variety of ways. In some embodiments, inhaled NO is administered continuously. In some embodiments, inhaled NO is administered intermittently. For example, the inhaled NO can be delivered twice a day, three times a day, or up to 10 times a day to prevent infections.
In some embodiments, the inhaled NO is delivered in a pulsed manner by sensing inspiratory effort. In some embodiments, the inhaled NO is delivered every nth breath. In some embodiments, the inhaled NO is delivered to a breath according to a timing schedule (every nth minute.
In some embodiments, the inhaled NO is delivered continuously without pulsing.
In some embodiments, the inhaled NO is given for days to months to years.
In some embodiments, the inhaled NO is delivered into a nasal cannula, a facemask, or a whole facemask.
In some embodiments, an oronasal mask can be used to remove infectious particles from the inhaled air. This can be used when the nitric oxide is generated from a stationary or a portable electrical NO generator or from another course.
In some embodiments, the facemask or the nasal cannula itself incorporates an electrical NO generator.
Architecture
System Design
An exemplary NO generation device 230 is depicted in
Reactant gas enters this exemplary system (room air in), passing through a filter 238. Other reactant gas conditioning steps are possible (not shown), including but not limited to VOC removal, NOx removal, liquid water removal, water vapor removal, etc. A pump 240 pressurizes the reactant gas and a flow dampener 242 removes some or all of the pressure and flow pulsations from the pump in the reactant gas. Flow dampening improves the accuracy of the reactant gas flow measurement and provides more stable pressure and flow within the plasma chamber for improved NO production consistency. After flowing through a reactant gas flow sensor 244, reactant gas flows into a plasma chamber 246.
Within the plasma chamber are one or more pairs of electrodes. Electrodes can be of many types including but not limited to gliding arc, opposed, parallel, torch, gliding torch, triple electrodes, dielectric barrier, microwave and other types. NO is generated within the plasma chamber when energy in the form of high voltage or RF energy is applied to the electrodes to a level that induces breakdown in the reactant gas between the electrodes. NO-containing product gas passes through a scrubber 248, a filter 250, and a check valve 252 prior to being introduced to the inspiratory flow. In some embodiments, a filter is also located upstream of the scrubber to prevent migration of scrubber media and capture particulate from the electrodes. The check valve ensures unidirectional flow from the NO device into the inspiratory flow with no losses of inspiratory flow. In some embodiments, multiple plasma chambers and/or multiple electrode gaps are utilized simultaneously to generate a target amount of NO.
As shown in
Additional features of the system depicted in
A pressure relief valve between the plasma chamber and scrubber protects the system from over-pressurization resulting from a clogged scrubber, kinked line, clogged filter, failed check valve and excessive inspiratory pressure. In some embodiments, a NOx scrubber is located after the pressure relief valve to scrub product gas before release into the atmosphere. In some embodiments, a pressure relief valve is instrumented with a position sensor, pressure sensor, flow sensor, or other type of transducer that can inform the NO device controller that the valve has been actuated. In some embodiments, a NO device controller monitors the pressure within the NO generation system. In some embodiments, a NO controller ceases reactant gas flow and/or plasma activity when an over-pressure event is detected. In some embodiments, a NO controller generates an audible and/or visual alarm when an over-pressure event occurs.
In the depicted embodiment, reactant gas is provided from a pressurized source so that no internal pump is required. The scrubber is located within the inspiratory limb, after blending of inspiratory gas and NO containing gas. Oxygen is added last to minimize NO production. In some embodiments, NO gas is scrubbed of NO2 prior to merging with either the inspiratory gas flow or the oxygen gas flow.
Flow Sensors
Flow sensors can be located within the enclosure of the NO generation device, with inspiratory, oxygen and other gases flowing through the NO generation device. Various types of flow sensors can be utilized (e.g. delta-pressure, hot wire, pressure anemometer, ultrasonic, paddle wheel, positive displacement, mass flow, etc.). In some embodiments, pressure, temperature, humidity, and volumetric flow rate are measured and utilized to determine a mass flow rate. In some embodiments, gases are blended within the NO generation device. In some embodiments, gases pass through the NO generation device for measurement purposes but only merge at or near the patient. This approach can help to minimize NO2 formation, for example in cases with elevated inspired oxygen levels, by mixing NO with oxygen as late as possible before patient delivery.
Alternatively, flow sensors can be located remotely from the NO generation device. In some embodiments, separate flow sensors measure oxygen flow to a patient in an oxygen line and the rate of medical air in another line. In some embodiments, external flow sensors connect to the NO generation device wirelessly. In some embodiments, wired connections exist. In some embodiments, a custom tubing set is used for treatments that includes embedded wires for sensor communications. This decreases user-steps and improves system reliability by decreasing the quantity of cables that could be tangled or pulled during treatment.
System Components
Reactant Gas Source
Reactant gas for NO generation can be sourced from house compressed air, a gas cylinder, or ambient air. In some embodiments, separate O2 and N2 tanks are used.
Reactant Gas Filter
Reactant gas can be filtered prior to entering the system. In some embodiments, reactant gas is filtered to 20 microns. In some embodiments, it is filtered to 0.22 micron.
Reactant Gas Scrubber
NO generators that utilize ambient air for reactant gas benefit from purifying the air prior to sending reactant gas through the plasma chamber. This approach decreases the number of compounds that can be created in the plasma chamber and decreases the potential of deposition of solids within the plasma chamber from solid compounds formed plasma chemistry. In some embodiments, reactant gas is scrubbed for VOCs, formaldehyde, ammonia, chloromethane, bleach and other compounds prior to entering the plasma chamber. Reactant gas scrubbers can be constructed of one or more of activated carbon, potassium permanganate, sodium metabisulfite (for formaldehyde), soda lime, acid (e.g. sulfuric acid for ammonia), and other compounds. In some embodiments the scrubber materials are mixed in a single scrubbing unit. In other embodiments, there is a series of scrubbers that the reactant gas passes through to prevent cross-scrubber chemical reactions. For example, acid scrubbers and alkaline scrubbers (soda lime) are separate to prevent reactions.
Reactant Gas Humidity Management
NO generators also can remove some or all of the water content within the reactant gas prior to flowing through the plasma chamber. This reduces the potential of water condensation within the system and makes the plasma chamber inputs more consistent for predictable NO generation.
Gas Flow
Reactant gas flow through a high concentration NO generation device can be the result of a pressure gradient across the device or propelled by a pump. In some embodiments, the NO generation device receives a NO target concentration value from a user, measures the inspiratory gas flow rate and determines an appropriate NO generation level (concentration*flow) accordingly. In some embodiments, a NO generation device is designed to only make one concentration of NO. In some embodiments, a NO generation device operates at a constant flow rate and NO production level. In some embodiments, a NO generation device produces 1500 ppm NO at 10 lpm and relies on the user to plumb the NO into a delivery device.
In some embodiments, part or all of the inspiratory flow serves as reactant gas for the NO generator. This approach is effective for prophylactic treatment of care providers that do not require additional oxygen because the patient is seemingly healthy and can breathe normally. This approach can also work in cases where supplemental oxygen is utilized. In some embodiments, the user provides the O2 concentration within the reactant gas to the NO generation device. In some embodiments, the NO generation device measures the O2 concentration of reactant gas. In embodiments where reactant gas oxygen levels can vary, a NO generation system includes a look-up table or formula to determine plasma parameters required to generate a known quantity of NO. Plasma parameters include, for example, energy, voltage, current, duty cycle, frequency, AC waveform, dithering, etc.
Pressure Relief Valve
In some embodiments, a pressure relief valve is included within the system to protect the system from a downstream obstruction. A pressure relief valve can prevent damage to the scrubber, plasma chamber and other parts of the system. Obstructions can occur due to a myriad of scenarios, including but not limited to a kinked line, a clogged scrubber, failed valve, blocked injector or other issues. When a pressure relief valve is located after the plasma chamber, gas relieved by the valve can contain some level of NO and NO2. In some embodiments, a NO2 and/or NOx scrubber is located in the exhaust path of a pressure relief valve to clean exhausted gas prior to release into the environment.
In some embodiments, a pressure relief valve is included within an inspiratory limb. This can prevent a NO generation system from over-pressurizing the lungs of a patient. In some embodiments, a NO generator includes a pressure sensor that measures inspiratory limb pressure. In some embodiments, a NO generation system ceases delivery of NO to an inspiratory limb when inspiratory limb pressure exceeds a threshold.
Product Gas Scrubber
The process of NO generation also produces NO2. NO2 can be chemically scrubbed from the NO product gas using soda lime, for example. In some embodiments, the scrubber material is packaged in a user-replaceable cartridge. In some embodiments, a scrubber cartridge contains 36 g of soda lime that provides a system with more than 16 hours of treatment at 200 ppm NO in 20 lpm.
Inhaled Gas Scrubber
In some embodiments, inspiratory flows of gas are scrubbed for NO2 prior to inhalation.
In some embodiments, filter material is located within the inhaled gas scrubber assembly after the scrubber material to remove scrubber material particles from the inspiratory gas material. In some embodiments, a separate filter component is connected to the inspiratory gas scrubber by either the patient or clinical user.
Electrodes
In some embodiments, a pair of electrodes are separable. One electrode can be replaced while the other electrode residing within the controller can be replaced at a different frequency, if replacement is required at all. In some embodiments, an electrode pair consists of a concentric rod and cylinder. In some embodiments, the outer electrode has a conical shape. The rod wears faster than the cylinder due to its lower surface area. In some embodiments, the rod is part of a replaceable cartridge. In some embodiments, the rod is part of a scrubber cartridge, reducing the number of use steps required to maintain electrodes. A similar approach can be achieved with the center electrode consisting of a needle, a cone or a point. The outer electrode can be in the form of a ring as well. Neither electrode has to be constrained to round shapes. For example, the outer electrode could be square in cross-section or some other polygon shape. In some embodiments, the outer electrode has splines that increase the electrical field between inner and outer electrode in discrete regions to facilitate break-down of the reactant gas.
Environmental Compensation
In some embodiments, a NO generation device includes a sensor to measure the characteristics of reactant gas. Reactant gas parameters measured include one or more of pressure, humidity, temperature, O2 concentration, N2 concentration, and flow rate. In some embodiments, ambient pressure, temperature and humidity are measured and used as inputs into the dose control algorithm. These gas measurements can be made before, within, and/or after the plasma chamber. In some embodiments, the controller uses reactant gas and/or ambient gas sensor measurements as an input to determine the reactant gas flow rate and/or plasma sparking characteristics.
Gas Measurement
In some embodiments, a NO device includes a built-in gas analyzer. In some embodiments, a gas analyzer is a separate and/or separable device from a NO generator. In some embodiments, the gas analyzer draws sample gas from a gas source and does one or more of the following: communicates wired or wirelessly with a NO generator, generates alarms, presents gas reading information. In some embodiments, gas measurements from the gas analyzer provide input into a closed-loop control scheme within a NO device to accurately achieve a NO dose target and/or minimize NO2 levels. In some embodiments, the gas analyzer consists of a module that can be inserted in series or parallel with an inspiratory flow stream. In some embodiments, this approach eliminates the need for sample lines, water traps, filters, and the like. In some embodiments, a gas analyzer has one or more sensors for NO, NO2 and O2 that are in fluid communication with the gas within an inspiratory limb. This can reduce the delay of gas sensors by eliminating the transit time of sample gas from an inspiratory limb to a remote gas sensor bench. In addition, a wireless remote gas sensor bench can eliminate the potential for wires and tubes to tangle near the patient. It can also improve gas sensor accuracy because the shorter transit time results in less NO2 formation.
In some embodiments, one or more sensors can be printed on a flex circuit or PCB, for example, to reduce size and weight. In some embodiments, the system can be operated with a coin cell and be disposable. In some embodiments, it wirelessly communicates to a NO generator. In some embodiments, a gas analyzer also measures a gas flow rate.
The gas analyzer can communicate with any of the devices disclosed herein, including but not limited to a NO generation device, a NO delivery device, a ventilator, a handheld device, and a cell phone or other remote device. Communication can be achieved using a variety of methods, including Bluetooth, ethernet, WiFi, etc.
The device in
Continuing with
The removable gas measurement device can communicate using any method, including wired (ethernet, RS232, USB, for example) or wirelessly (Wi-Fi, ZigBee, Bluetooth, Infrared, for example). Devices receiving information from the gas sensor assembly can include but are not limited to NO generation devices, NO deliver devices, ventilators, CPAP systems, hand-held monitors, patient monitors, cell phones, and PCs.
In some embodiments, the gas sensors are printed on a printed circuit board or flex circuit and powered by a coin cell, enabling a very small and lightweight gas analyzer to be constructed. In some embodiments, the gas analyzer is disposable. In some embodiments, the gas analyzer is reusable, requiring only periodic battery changes and cleaning.
The device in
In addition to collecting gas concentration data from the gas sensors, the controller can also monitor the health of the sensors, tracking sensor drift and calibration settings. In some embodiments, the controller can step a user through a sensor calibration process whereby the user subjects the sensors to controlled levels of specific gases. Sensor output for each gas concentration is used to generate calibration settings for the sensor. In some embodiments, a gas sensor includes a memory device (e.g. EPROM) that includes information such as the date of manufacture, expiration date, calibration coefficients, sensor battery level, sensor part number, sensor version number, sensor range, and other information.
The side stream of sample gas is typically a low flow rate (e.g. 100-1000 ml/min). In some treatments, the sampled gas is humidified (e.g. 100% RH at 37 deg C.). In the case of humidified sample gas, some embodiments have one or more of a water trap, humidity exchange tubing, or other means to remove water from the sample before exposing the gas sensors. In some embodiments, the gas sensor chamber is insulated to minimize heat loss around the inspiratory flow tube and prevent condensation. In some embodiments, the gas sensor chamber is actively warmed to 37 deg C. or higher to prevent condensation within the gas sensor pneumatic pathway. In the embodiment depicted in
Prolonged and/or high dose NO therapy can result in elevated methemoglobin levels. In some embodiments, a NO generation and/or delivery device either includes a methemoglobin measurement capability or communicates with a methemoglobin analyzer. In some embodiments, a NO generation and/or delivery device will not permit NO therapy to begin until a methemoglobin measurement is received. In some embodiments, the NO generation and/or delivery device either stops treatment or lowers the dose in the presence of elevated methemoglobin levels. In some embodiments, a NO generation and/or delivery device cannot start treatment if methemoglobin levels are already high. In some embodiments, a NO generation and/or delivery device can resume treatment automatically when methemoglobin levels return to a particular level.
In some embodiments, a NO generation device limits the amount of NO that can be delivered over a period of time. In some embodiments, a NO generation device permits NO dosing of a specific number of breaths per unit time. For example, 3 breaths every minute, or 20 breaths in an hour. The actual NO dose limitation can be based on one or more of the desired NO dose in mg/hr, the patient size, the patient's lung volume, the patient condition (type of infection for example), measured methemoglobin levels, or SpO2 levels.
The electrodes can be formed from a variety of pure materials, including alloys of hafnium, iridium, tungsten, silver, ruthenium, stainless steel, and platinum. For example, an alloy of iridium-tungsten, platinum-iridium, hafnium iridium, tungsten iridium, tungsten silver can be used.
In some embodiments, all gas flow rates are constant. This simplifies the task of generating and delivering an accurate amount of NO.
NO/air/O2 gas passes to a patient wearing a non-rebreather mask. The reservoir (bag) connected to the inspiratory line fills between breaths at a slow and constant rate. The patient inhales gas from the reservoir, thereby emptying the reservoir. The gas flow rate filling the reservoir is targeted to match the patient inspiratory minute volume so that the reservoir doesn't fully collapse during inhalation or gradually increase in volume and/or pressure.
It will be understood that the systems and methods disclosed herein can be used in a variety of clinical applications and infectious indications, including but not limited to:
Exemplary instructions for use of the devices described herein are provided.
Device Description
eNOX-200 Nitric Oxide generation system is a portable investigational device that electrically generates Nitric Oxide (eNO) from ambient air using a plasma-based approach and delivers NO concentrations between 100-200 ppm to the patient. The device enables users to customize NO delivery to meet the respiratory needs of a spontaneously breathing patient by automatically accommodating variable inspiratory flow rates or by manually entering expected inspiratory flow rates.
Intended Use
The intended use of the eNOX-200 device is for investigational use only to support IRB-approved clinical trials under an investigational device exemption (IDE) to potentially prevent progression of COVID-19 in spontaneously breathing patients with mild to moderate symptoms and to potentially prevent SARS-Cov-2 infection in healthcare workers. The use specifications (i.e. intended users, use environment, and patient population) are determined by IRB-approved clinical trial protocols.
Theory of Operation
The eNOX-200 injects a fixed 2.8 L/min flow of electrically produced NO (eNO) into the patient breathing circuit. The flow inspired by the patient is total of eNO flow, medical air flow, and supplemental oxygen flow. The concentration of eNO produced and delivered varies based on the NO concentration target level set by the user and the inspiratory flow of medical air and/or supplemental oxygen delivered to the patient. The schematic diagram of the system is shown in
The eNOX-200 generates medical grade NO for inhalation from ambient air. A HEPA filter at the ambient room air intake into the eNOX-200 removes unwanted particles and prevents contamination from the room air which then is pumped into the plasma chamber that combines nitrogen and oxygen by plasma technology. A Gas Filter Tube containing soda lime then purifies NO by removing contaminants and nitrogen dioxide (NO2). The resulting gas output is electrically produced NO (eNO), which is a mixture of air and NO. The Gas Filter Tube is a multipatient consumable component which must be changed after 16 hours of unpacking whether it was in use or not within the 16 hours.
The system has two eNO flow output route options for connection to patient breathing circuit: (1) Flow OUT−The eNO gas is injected into the pass-through inspiratory flow channel to mix with medical air to output eNO+medical air into patient breathing circuit, and (2) eNO output−The eNO gas from eNOX-200 can be directly injected into the patient breathing tube.
The system has two basic modes of operation. In AUTO MODE, the user selects the NO target level and passes the medical air through (Flow IN) inspiratory air flow channel of the device. The system measures the inspiratory air flow and automatically determines the required concentration of eNO to inject into the inspiratory air flow in order to reach the selected target levels of NO concentrations after dilution of eNO into inspiratory air flow. In MANUAL MODE, the user selects the NO target level AND manually selects the flow rate of the inspiratory flow air, which could include either or both medical air flow and supplemental oxygen air flow. The system determines the required concentration of eNO to inject into the inspiratory air flow in order to reach the selected target levels of NO concentrations after dilution of eNO into inspiratory air flow. The system also incorporates additional safety features such as pressure relief valves, and flow sensors, as well as internal software self-monitoring checks to ensure that operational issues are monitored and managed.
System Setup
User may customize and update the patient breathing assembly setup in accordance with an IRB-approved clinical trial protocol. The following are potential configurations for device connection to a patient breathing assembly and/or Non-invasive ventilation. The intent of the figures and text in this section is to demonstrate the type of connections that can be made to and from the eNOX-200 device in different modes of operation. The patient breathing assembly set up shown in the figures below is for reference only.
If the patient requires supplemental oxygen, connect the supplemental oxygen directly to the patient breathing circuit close the patient face mask, as shown in
The device can be set up to inject eNO into the medical air prior to patient breathing circuit connections, or directly into patient breathing circuit. To inject eNO into the medical air prior to patient breathing circuit, the medical air is passed through the eNOX-200. To inject the eNO directly into the patient breathing circuit, medical air bypasses the eNOX-200. If you are passing medical air through the eNOX-200, set up the system as shown in
If you are bypassing the eNOX-200 to deliver medical air, set up the system as shown in
If the patient does not require supplemental oxygen, it is recommended to set up the system to pass medical air through the eNOX-200, as shown in
Delivering NO
An exemplary method for delivering NO includes:
NO Delivery Management
An exemplary method for managing NO delivery includes:
Alarms and Troubleshooting
Maintenance
Maintenance of the system can include:
Technical Specifications
The following is a listing of exemplary technical specifications for the system in the example.
All patents, patent applications, and published references cited herein are hereby incorporated by reference in their entirety. It will be appreciated that several of the above-disclosed and other features and functions, or alternatives thereof, may be desirably combined into many other different systems or application. Various alternatives, modifications, variations, or improvements therein may be subsequently made by those skilled in the art.
This application is a continuation patent application of U.S. application Ser. No. 17/352,225 filed Jun. 18, 2021, which claims the benefit of and priority to U.S. Provisional Application No. 63/194,145 filed May 27, 2021, U.S. Provisional Application No. 63/159,981 filed Mar. 11, 2021, and U.S. Provisional Application No. 63/040,982 filed Jun. 18, 2020, and the contents of each of these applications are hereby incorporated herein by reference in their entireties.
| Number | Name | Date | Kind |
|---|---|---|---|
| 709867 | Bradley et al. | Sep 1902 | A |
| 2485478 | Cotton | Oct 1949 | A |
| 2485481 | Cotton | Oct 1949 | A |
| 2525938 | Peck | Oct 1950 | A |
| 2684448 | Nilles | Jul 1954 | A |
| 3047370 | Aviges et al. | Jul 1962 | A |
| 3225309 | Phelps | Dec 1965 | A |
| 4287040 | Alamaro | Sep 1981 | A |
| 4500563 | Ellenberger et al. | Feb 1985 | A |
| 4505795 | Alamaro | Mar 1985 | A |
| 4680694 | Huynh et al. | Jul 1987 | A |
| 4695358 | Mizuno et al. | Sep 1987 | A |
| 4705670 | O'Hare | Nov 1987 | A |
| 4816229 | JeRnsen et al. | Mar 1989 | A |
| 4877589 | Conrad | Oct 1989 | A |
| 5285372 | Huynh et al. | Feb 1994 | A |
| 5378436 | Endoh et al. | Jan 1995 | A |
| 5396882 | Zapol | Mar 1995 | A |
| 5413097 | Birenheide et al. | May 1995 | A |
| 5471977 | Olsson et al. | Dec 1995 | A |
| 5485827 | Zapol et al. | Jan 1996 | A |
| 5531218 | Krebs | Jul 1996 | A |
| 5546935 | Champeau | Aug 1996 | A |
| 5558083 | Bathe et al. | Sep 1996 | A |
| 5573733 | Salama | Nov 1996 | A |
| 5674381 | Dekker | Oct 1997 | A |
| 5692495 | Sheu | Dec 1997 | A |
| 5732693 | Bathe et al. | Mar 1998 | A |
| 5749937 | Detering et al. | May 1998 | A |
| 5752504 | Bathe | May 1998 | A |
| 5827420 | Shirazi et al. | Oct 1998 | A |
| 5839433 | Higenbottam | Nov 1998 | A |
| 5845633 | Psaros | Dec 1998 | A |
| 6089229 | Bathe et al. | Jul 2000 | A |
| 6109260 | Bathe | Aug 2000 | A |
| 6125846 | Bathe et al. | Oct 2000 | A |
| 6164276 | Bathe et al. | Dec 2000 | A |
| 6186140 | Hoague | Feb 2001 | B1 |
| 6186142 | Schmidt et al. | Feb 2001 | B1 |
| 6197091 | Ji et al. | Mar 2001 | B1 |
| 6224653 | Shvedchikov et al. | May 2001 | B1 |
| 6250302 | Rantala | Jun 2001 | B1 |
| 6290683 | Erez et al. | Sep 2001 | B1 |
| 6296827 | Castor et al. | Oct 2001 | B1 |
| 6365868 | Borowy et al. | Apr 2002 | B1 |
| 6432077 | Stenzler | Aug 2002 | B1 |
| 6532956 | Hill | Mar 2003 | B2 |
| 6536429 | Pavlov et al. | Mar 2003 | B1 |
| 6581599 | Stenzler | Jun 2003 | B1 |
| 6668828 | Figley et al. | Dec 2003 | B1 |
| 6758214 | Fine et al. | Jul 2004 | B2 |
| 6920876 | Miller et al. | Jul 2005 | B2 |
| 6955171 | Figley et al. | Oct 2005 | B1 |
| 6955790 | Castor et al. | Oct 2005 | B2 |
| 6984256 | Lamprecht et al. | Jan 2006 | B2 |
| 6986351 | Figley et al. | Jan 2006 | B2 |
| 7025869 | Fine et al. | Apr 2006 | B2 |
| 7040313 | Fine et al. | May 2006 | B2 |
| 7122018 | Stenzler et al. | Oct 2006 | B2 |
| 7220393 | Miller et al. | May 2007 | B2 |
| 7255105 | Figley et al. | Aug 2007 | B2 |
| 7299785 | Lee | Nov 2007 | B1 |
| 7312584 | Tamita et al. | Dec 2007 | B2 |
| 7335181 | Miller et al. | Feb 2008 | B2 |
| 7485324 | Miller et al. | Feb 2009 | B2 |
| 7498000 | Pekshev et al. | Mar 2009 | B2 |
| 7516742 | Stenzler et al. | Apr 2009 | B2 |
| 7520866 | Stenzler et al. | Apr 2009 | B2 |
| 7523752 | Montgomery et al. | Apr 2009 | B2 |
| 7531133 | Hole et al. | May 2009 | B2 |
| 7560076 | Rounbehler et al. | Jul 2009 | B2 |
| 7589473 | Suslov | Sep 2009 | B2 |
| 7597731 | Palmerton et al. | Oct 2009 | B2 |
| 7618594 | Rounbehler et al. | Nov 2009 | B2 |
| 7744812 | Witherspoon et al. | Jun 2010 | B2 |
| 7861516 | Allanson et al. | Jan 2011 | B2 |
| 7861717 | Krebs | Jan 2011 | B1 |
| 7914743 | Fine et al. | Mar 2011 | B2 |
| 7947227 | Fine et al. | May 2011 | B2 |
| 7955294 | Stenzler et al. | Jun 2011 | B2 |
| 8030849 | Suslov | Oct 2011 | B2 |
| 8043252 | Miller et al. | Oct 2011 | B2 |
| 8057742 | Rounbehler et al. | Nov 2011 | B2 |
| 8066904 | Fine et al. | Nov 2011 | B2 |
| 8079998 | Hole et al. | Dec 2011 | B2 |
| 8083997 | Rounbehler et al. | Dec 2011 | B2 |
| 8091549 | Montgomery et al. | Jan 2012 | B2 |
| 8151791 | Arlow et al. | Apr 2012 | B2 |
| 8173072 | Fine et al. | May 2012 | B2 |
| 8187544 | Fine et al. | May 2012 | B2 |
| 8211368 | Fine et al. | Jul 2012 | B2 |
| 8221800 | Fine et al. | Jul 2012 | B2 |
| 8226916 | Rounbehler et al. | Jul 2012 | B2 |
| 8246725 | Rounbehler et al. | Aug 2012 | B2 |
| 8267884 | Hicks | Sep 2012 | B1 |
| 8268252 | Fuller et al. | Sep 2012 | B2 |
| 8277399 | Hamilton et al. | Oct 2012 | B2 |
| 8282966 | Baldassarre et al. | Oct 2012 | B2 |
| 8291904 | Bathe et al. | Oct 2012 | B2 |
| 8293284 | Baldassarre et al. | Oct 2012 | B2 |
| 8328998 | Wada et al. | Dec 2012 | B2 |
| 8344627 | Hooke et al. | Jan 2013 | B1 |
| 8371296 | Fine et al. | Feb 2013 | B2 |
| 8377462 | DesNoyer et al. | Feb 2013 | B2 |
| 8397721 | Montgomery et al. | Mar 2013 | B2 |
| D679366 | Fuller | Apr 2013 | S |
| 8408206 | Montgomery et al. | Apr 2013 | B2 |
| 8431163 | Baldassarre et al. | Apr 2013 | B2 |
| D688352 | Montgomery et al. | Aug 2013 | S |
| 8518457 | Miller et al. | Aug 2013 | B2 |
| 8573209 | Bathe et al. | Nov 2013 | B2 |
| 8573210 | Bathe et al. | Nov 2013 | B2 |
| 8574531 | Miller et al. | Nov 2013 | B2 |
| 8580109 | Kruckenberg et al. | Nov 2013 | B2 |
| 8607785 | Fine et al. | Dec 2013 | B2 |
| 8607792 | Montgomery et al. | Dec 2013 | B2 |
| 8609026 | Fine et al. | Dec 2013 | B2 |
| 8609028 | Rounbehler et al. | Dec 2013 | B2 |
| 8613958 | Fine | Dec 2013 | B2 |
| 8616204 | Montgomery et al. | Dec 2013 | B2 |
| 8646445 | Fine et al. | Feb 2014 | B2 |
| D701963 | Abarbanel et al. | Apr 2014 | S |
| 8685467 | Miller et al. | Apr 2014 | B2 |
| 8701657 | Fine et al. | Apr 2014 | B2 |
| 8715577 | Fine et al. | May 2014 | B2 |
| 8717733 | Gefter et al. | May 2014 | B2 |
| 8720440 | Montgomery et al. | May 2014 | B2 |
| 8741222 | Fine et al. | Jun 2014 | B2 |
| 8757148 | Montgomery et al. | Jun 2014 | B2 |
| 8770199 | Flanagan et al. | Jul 2014 | B2 |
| 8776794 | Bathe et al. | Jul 2014 | B2 |
| 8776795 | Bathe et al. | Jul 2014 | B2 |
| 8790715 | Montgomery et al. | Jul 2014 | B2 |
| 8795222 | Stenzler et al. | Aug 2014 | B2 |
| 8795741 | Baldassarre | Aug 2014 | B2 |
| 8808655 | Solovyov et al. | Aug 2014 | B2 |
| 8821801 | Rounbehler et al. | Sep 2014 | B2 |
| 8821828 | Hilbig et al. | Sep 2014 | B2 |
| 8846112 | Baldassarre | Sep 2014 | B2 |
| 8887720 | Fine et al. | Nov 2014 | B2 |
| 8893717 | Montgomery et al. | Nov 2014 | B2 |
| 8944049 | Fine et al. | Feb 2015 | B2 |
| 9035045 | Chu et al. | May 2015 | B2 |
| 9067788 | Spielman et al. | Jun 2015 | B1 |
| 9095534 | Stenzler et al. | Aug 2015 | B2 |
| 9108016 | Acker et al. | Aug 2015 | B2 |
| 9180217 | Arnold et al. | Nov 2015 | B2 |
| 9192718 | Fine | Nov 2015 | B2 |
| 9260399 | Ruan et al. | Feb 2016 | B2 |
| 9265911 | Bathe et al. | Feb 2016 | B2 |
| 9279794 | Tolmie et al. | Mar 2016 | B2 |
| 9295802 | Bathe et al. | Mar 2016 | B2 |
| 9351994 | Montgomery et al. | May 2016 | B2 |
| 9408994 | Fine et al. | May 2016 | B2 |
| 9408993 | Bathe et al. | Aug 2016 | B2 |
| 9522249 | Rounbehler et al. | Dec 2016 | B2 |
| 9550039 | Flanagan et al. | Jan 2017 | B2 |
| 9550040 | Acker et al. | Jan 2017 | B2 |
| 9562113 | Ruan et al. | Feb 2017 | B2 |
| 9573110 | Montgomery et al. | Feb 2017 | B2 |
| 9604028 | Fine et al. | Mar 2017 | B2 |
| 9701538 | Fine et al. | Jul 2017 | B2 |
| 9713244 | Tabata et al. | Jul 2017 | B2 |
| 9770570 | Schnictman et al. | Sep 2017 | B2 |
| 9795756 | Flanagan et al. | Oct 2017 | B2 |
| 9895199 | Montgomery et al. | Feb 2018 | B2 |
| 9896337 | Montgomery et al. | Feb 2018 | B2 |
| 9956373 | Rounbehler et al. | May 2018 | B2 |
| 9982354 | Kim | May 2018 | B2 |
| 10081544 | Fine et al. | Sep 2018 | B2 |
| 10086352 | Fine et al. | Oct 2018 | B2 |
| 10099029 | Montgomery et al. | Oct 2018 | B2 |
| 10124142 | Rounbehler et al. | Nov 2018 | B2 |
| 10179222 | Fine et al. | Jan 2019 | B2 |
| 10188822 | Flanagan et al. | Jan 2019 | B2 |
| 10213572 | Gellman et al. | Feb 2019 | B2 |
| 10226592 | Acker et al. | Mar 2019 | B2 |
| 10232138 | Acker et al. | Mar 2019 | B2 |
| 10239038 | Zapol et al. | Mar 2019 | B2 |
| 10279139 | Zapol et al. | May 2019 | B2 |
| 10286176 | Zapol et al. | May 2019 | B2 |
| 10293133 | Zapol et al. | May 2019 | B2 |
| 10328228 | Zapol et al. | Jun 2019 | B2 |
| 10398820 | Potenziano et al. | Sep 2019 | B2 |
| 10426913 | Tolmie et al. | Oct 2019 | B2 |
| 10434276 | Zapol et al. | Oct 2019 | B2 |
| 10532176 | Zapol et al. | Jan 2020 | B2 |
| 10548920 | Montgomery et al. | Feb 2020 | B2 |
| 10556082 | Flanagan et al. | Feb 2020 | B2 |
| 10556086 | Goldstein et al. | Feb 2020 | B2 |
| 10576239 | Zapol et al. | Mar 2020 | B2 |
| 10646682 | Zapol et al. | May 2020 | B2 |
| 10682486 | Moon et al. | Jun 2020 | B1 |
| 10695523 | Zapol et al. | Jun 2020 | B2 |
| 10737051 | Gellman et al. | Aug 2020 | B2 |
| 10750606 | Liu et al. | Aug 2020 | B1 |
| 10758703 | Kohlmann et al. | Sep 2020 | B2 |
| 10773046 | Schnitman et al. | Sep 2020 | B2 |
| 10773047 | Zapol et al. | Sep 2020 | B2 |
| 10780241 | Fine et al. | Sep 2020 | B2 |
| 10814092 | Rounbehler et al. | Oct 2020 | B2 |
| 10946163 | Gillerman et al. | Mar 2021 | B2 |
| 11007503 | Zapol et al. | May 2021 | B2 |
| 11033705 | Zapol et al. | Jun 2021 | B2 |
| 11045620 | Hall et al. | Jun 2021 | B2 |
| 11376390 | Gillerman et al. | Jul 2022 | B2 |
| 11478601 | Hall et al. | Oct 2022 | B2 |
| 11479464 | Hall et al. | Oct 2022 | B2 |
| 11524134 | Zapol et al. | Dec 2022 | B2 |
| 11554240 | Hall et al. | Jan 2023 | B2 |
| 11660416 | McAuley et al. | May 2023 | B2 |
| 11691879 | Kondiboyina et al. | Jul 2023 | B2 |
| 20010031230 | Castor et al. | Oct 2001 | A1 |
| 20010035186 | Hill | Nov 2001 | A1 |
| 20020111748 | Kobayashi et al. | Aug 2002 | A1 |
| 20020185126 | Krebs | Dec 2002 | A1 |
| 20040019274 | Galloway, Jr. et al. | Jan 2004 | A1 |
| 20040028753 | Hedenstierna et al. | Feb 2004 | A1 |
| 20040031248 | Lindsay | Feb 2004 | A1 |
| 20040050387 | Younes | Mar 2004 | A1 |
| 20040149282 | Hickle | Aug 2004 | A1 |
| 20040168686 | Krebs | Sep 2004 | A1 |
| 20040181149 | Langlotz et al. | Sep 2004 | A1 |
| 20050172971 | Kolobow et al. | Aug 2005 | A1 |
| 20050218007 | Pekshev et al. | Oct 2005 | A1 |
| 20050263150 | Chathampally et al. | Dec 2005 | A1 |
| 20050274381 | Deane et al. | Dec 2005 | A1 |
| 20050281465 | Marquart et al. | Dec 2005 | A1 |
| 20060025700 | Fallik | Feb 2006 | A1 |
| 20060090759 | Howes et al. | May 2006 | A1 |
| 20060172018 | Fine et al. | Aug 2006 | A1 |
| 20060173396 | Hatamian et al. | Aug 2006 | A1 |
| 20060207594 | Stenzler et al. | Sep 2006 | A1 |
| 20060276844 | Alon et al. | Dec 2006 | A1 |
| 20070051712 | Kooken et al. | Mar 2007 | A1 |
| 20070113851 | Delisle et al. | May 2007 | A1 |
| 20070151561 | Laurila | Jul 2007 | A1 |
| 20070181126 | Tolmie et al. | Aug 2007 | A1 |
| 20070190184 | Montgomery et al. | Aug 2007 | A1 |
| 20080017030 | Fleck | Jan 2008 | A1 |
| 20080078382 | LeMahieu et al. | Apr 2008 | A1 |
| 20080135044 | Freitag et al. | Jun 2008 | A1 |
| 20080176335 | Alberti et al. | Jul 2008 | A1 |
| 20080202509 | Dillon et al. | Aug 2008 | A1 |
| 20100030091 | Fine | Feb 2010 | A1 |
| 20100043789 | Fine et al. | Feb 2010 | A1 |
| 20100051025 | Zapol | Mar 2010 | A1 |
| 20100076325 | Cho et al. | Mar 2010 | A1 |
| 20100089392 | Fine et al. | Apr 2010 | A1 |
| 20100189808 | Gupta et al. | Jul 2010 | A1 |
| 20100275911 | Arlow et al. | Nov 2010 | A1 |
| 20100330193 | Baldassarre et al. | Dec 2010 | A1 |
| 20110140607 | Moore et al. | Jun 2011 | A1 |
| 20110240019 | Fine et al. | Oct 2011 | A1 |
| 20120093948 | Fine et al. | Apr 2012 | A1 |
| 20120279500 | Singvogel et al. | Nov 2012 | A1 |
| 20120285449 | Fine et al. | Nov 2012 | A1 |
| 20120296265 | Dobrynin et al. | Nov 2012 | A1 |
| 20130123801 | Umasuthan et al. | May 2013 | A1 |
| 20130150863 | Baumgartner | Jun 2013 | A1 |
| 20130239963 | Goldstein et al. | Sep 2013 | A1 |
| 20130309328 | Watts et al. | Nov 2013 | A1 |
| 20140020685 | Szabo | Jan 2014 | A1 |
| 20140031668 | Mobasser et al. | Jan 2014 | A1 |
| 20140127081 | Fine et al. | May 2014 | A1 |
| 20140127330 | Fine et al. | May 2014 | A1 |
| 20140144436 | Fine et al. | May 2014 | A1 |
| 20140144444 | Fine et al. | May 2014 | A1 |
| 20140158121 | Flanagan et al. | Jun 2014 | A1 |
| 20140166009 | Flanagan et al. | Jun 2014 | A1 |
| 20140216452 | Miller et al. | Aug 2014 | A1 |
| 20140251787 | Montgomery et al. | Sep 2014 | A1 |
| 20140363525 | Montgomery et al. | Dec 2014 | A1 |
| 20140377378 | Baldassarre | Dec 2014 | A1 |
| 20150000659 | Martin | Jan 2015 | A1 |
| 20150004248 | Morfill et al. | Jan 2015 | A1 |
| 20150034084 | Av-Gay et al. | Feb 2015 | A1 |
| 20150044305 | Av-Gay et al. | Feb 2015 | A1 |
| 20150072023 | Greenberg et al. | Mar 2015 | A1 |
| 20150075522 | Acker et al. | Mar 2015 | A1 |
| 20150090261 | Crosbie | Apr 2015 | A1 |
| 20150101604 | Crosbie | Apr 2015 | A1 |
| 20150174158 | Av-Gay et al. | Jun 2015 | A1 |
| 20150272988 | Av-Gay et al. | Oct 2015 | A1 |
| 20150328430 | Miller et al. | Nov 2015 | A1 |
| 20160022731 | Av-Gay et al. | Jan 2016 | A1 |
| 20160030699 | Zapol et al. | Feb 2016 | A1 |
| 20160038710 | Zapol et al. | Feb 2016 | A1 |
| 20160045685 | Hyde et al. | Feb 2016 | A1 |
| 20160106946 | Gellman et al. | Apr 2016 | A1 |
| 20160106949 | Kohlmann et al. | Apr 2016 | A1 |
| 20160121071 | Moon et al. | May 2016 | A1 |
| 20160151598 | Fine | Jun 2016 | A1 |
| 20160183841 | Duindam et al. | Jun 2016 | A1 |
| 20160191887 | Casas | Jun 2016 | A1 |
| 20160193336 | Nelson et al. | Jul 2016 | A1 |
| 20160228670 | Av-Gay et al. | Aug 2016 | A1 |
| 20160243328 | Tolmie et al. | Aug 2016 | A1 |
| 20160271169 | Potenziano et al. | Sep 2016 | A1 |
| 20160279165 | Av-Gay et al. | Sep 2016 | A1 |
| 20160324580 | Esterberg | Nov 2016 | A1 |
| 20160367775 | Tolmie et al. | Dec 2016 | A1 |
| 20170014571 | Deem et al. | Jan 2017 | A1 |
| 20170014591 | Tolmie et al. | Jan 2017 | A1 |
| 20170014592 | Tolmie et al. | Jan 2017 | A1 |
| 20170021124 | Tolmie et al. | Jan 2017 | A1 |
| 20170065631 | Av-Gay et al. | Mar 2017 | A1 |
| 20170112871 | Nelson et al. | Apr 2017 | A1 |
| 20170128694 | Acker et al. | May 2017 | A1 |
| 20170143758 | Greenberg et al. | May 2017 | A1 |
| 20170165294 | Dasse et al. | Jun 2017 | A1 |
| 20170182088 | Dasse et al. | Jun 2017 | A1 |
| 20170232166 | Potenziano et al. | Aug 2017 | A1 |
| 20170239289 | Av-Gay et al. | Aug 2017 | A1 |
| 20170259025 | Fine et al. | Sep 2017 | A1 |
| 20170296463 | Minton et al. | Oct 2017 | A1 |
| 20170348503 | Westermark | Dec 2017 | A1 |
| 20180049622 | Ryan et al. | Feb 2018 | A1 |
| 20180104432 | Flanagan et al. | Apr 2018 | A1 |
| 20180125883 | Av-Gay et al. | May 2018 | A1 |
| 20180126111 | Moon et al. | May 2018 | A1 |
| 20180133246 | Av-Gay et al. | May 2018 | A1 |
| 20180169370 | Montgomery et al. | Jun 2018 | A1 |
| 20180228836 | Nelson et al. | Aug 2018 | A1 |
| 20180243527 | Zapol et al. | Aug 2018 | A1 |
| 20180243528 | Zapol et al. | Aug 2018 | A1 |
| 20180264032 | Jaffri et al. | Sep 2018 | A1 |
| 20180280920 | Zapol et al. | Oct 2018 | A1 |
| 20180296790 | Zapol et al. | Oct 2018 | A1 |
| 20180304038 | Jafri et al. | Oct 2018 | A1 |
| 20180311460 | Rounbehler et al. | Nov 2018 | A1 |
| 20180328842 | Kjaer | Nov 2018 | A1 |
| 20190038864 | Montgomery et al. | Feb 2019 | A1 |
| 20190092639 | Fine et al. | Mar 2019 | A1 |
| 20190127223 | Montgomery et al. | May 2019 | A1 |
| 20190135633 | Montgomery et al. | May 2019 | A1 |
| 20190143068 | Rounbehler et al. | May 2019 | A1 |
| 20190184116 | Acker et al. | Jun 2019 | A1 |
| 20190209993 | Fine et al. | Jul 2019 | A1 |
| 20190217042 | Zapol et al. | Jul 2019 | A1 |
| 20190217043 | Fine et al. | Jul 2019 | A1 |
| 20190233288 | Montgomery et al. | Aug 2019 | A1 |
| 20190233289 | Montgomery et al. | Aug 2019 | A1 |
| 20190276313 | Montgomery et al. | Sep 2019 | A1 |
| 20190314596 | Zapol et al. | Oct 2019 | A1 |
| 20190374739 | Tolmie et al. | Dec 2019 | A1 |
| 20200030553 | Keip et al. | Jan 2020 | A1 |
| 20200094011 | Zapol et al. | Mar 2020 | A1 |
| 20200139071 | Fine et al. | May 2020 | A1 |
| 20200139072 | Zapol et al. | May 2020 | A1 |
| 20200139073 | Tector et al. | May 2020 | A1 |
| 20200163989 | Montgomery et al. | May 2020 | A1 |
| 20200171259 | Flanagan et al. | Jun 2020 | A1 |
| 20200171264 | Goldstein et al. | Jun 2020 | A1 |
| 20200180958 | Fine et al. | Jun 2020 | A1 |
| 20200188319 | Quinn et al. | Jun 2020 | A1 |
| 20200254199 | Bassin | Aug 2020 | A1 |
| 20200282375 | Fine et al. | Sep 2020 | A1 |
| 20200360647 | Quinn et al. | Nov 2020 | A1 |
| 20200360649 | Hall et al. | Nov 2020 | A1 |
| 20200360690 | Evans et al. | Nov 2020 | A1 |
| 20200361772 | Hall et al. | Nov 2020 | A1 |
| 20200361773 | Gillerman et al. | Nov 2020 | A1 |
| 20200390994 | Gillerman et al. | Dec 2020 | A1 |
| 20210214222 | Kondiboyia et al. | Jul 2021 | A1 |
| 20210220586 | Shah et al. | Jul 2021 | A1 |
| 20210268221 | Gillerman et al. | Sep 2021 | A1 |
| 20210330957 | Potenziano et al. | Oct 2021 | A1 |
| 20210353898 | Hall et al. | Nov 2021 | A1 |
| 20210386954 | Tamiya et al. | Dec 2021 | A1 |
| 20210395905 | Silkoff et al. | Dec 2021 | A1 |
| 20220047837 | Zapol et al. | Feb 2022 | A1 |
| 20220080147 | Shah et al. | Mar 2022 | A1 |
| 20220096535 | Shah et al. | Mar 2022 | A1 |
| 20220135406 | Apollonio et al. | May 2022 | A1 |
| 20220162070 | Silkoff et al. | May 2022 | A1 |
| 20220211967 | Hall et al. | Jul 2022 | A1 |
| 20220296845 | Jackson et al. | Sep 2022 | A1 |
| 20220339391 | Gillerman et al. | Oct 2022 | A1 |
| 20230001119 | Richardson et al. | Jan 2023 | A1 |
| 20230053201 | Miles et al. | Feb 2023 | A1 |
| 20230098706 | Miles et al. | Mar 2023 | A1 |
| 20230112963 | Yuen et al. | Apr 2023 | A1 |
| 20230149556 | Hall et al. | May 2023 | A1 |
| 20230158064 | Shah | May 2023 | A1 |
| 20230158260 | Shah et al. | May 2023 | A1 |
| 20230158261 | Trias et al. | May 2023 | A1 |
| 20230201497 | Dekker | Jun 2023 | A1 |
| 20230263986 | Hall et al. | Aug 2023 | A1 |
| Number | Date | Country |
|---|---|---|
| 2413834 | Jun 2004 | CA |
| 1099997 | Mar 1995 | CN |
| 1730115 | Feb 2006 | CN |
| 201037113 | Mar 2008 | CN |
| 100404083 | Jul 2008 | CN |
| 101036482 | Dec 2010 | CN |
| 110872714 | Mar 2020 | CN |
| 101 51 270 | Oct 2006 | DE |
| 621051 | Oct 1994 | EP |
| 0763500 | Mar 1997 | EP |
| 0878208 | Nov 1998 | EP |
| 1036758 | Sep 2000 | EP |
| 2151554 | Feb 2010 | EP |
| 1854494 | Jun 2012 | EP |
| 2565157 | Oct 2017 | EP |
| 3372267 | Dec 2018 | EP |
| H04132560 | May 1992 | JP |
| 2000102616 | Apr 2000 | JP |
| 2004065636 | Mar 2004 | JP |
| 2006273677 | Oct 2006 | JP |
| 100841741 | Jun 2008 | KR |
| 20100087977 | Aug 2010 | KR |
| 2199167 | Feb 2003 | RU |
| WO199507610 | Mar 1995 | WO |
| WO2004032719 | Apr 2004 | WO |
| WO2005094138 | Oct 2005 | WO |
| WO2005110441 | Nov 2005 | WO |
| WO2008019102 | Feb 2008 | WO |
| WO2008112143 | Sep 2008 | WO |
| 2008116991 | Oct 2008 | WO |
| WO2009018837 | Feb 2009 | WO |
| WO2010021944 | Feb 2010 | WO |
| WO2011002606 | Jan 2011 | WO |
| WO2012014805 | Feb 2012 | WO |
| WO2012034089 | Mar 2012 | WO |
| WO2012094008 | Jul 2012 | WO |
| WO2012155213 | Nov 2012 | WO |
| WO2013052548 | Apr 2013 | WO |
| WO2013070712 | May 2013 | WO |
| WO2013181179 | Dec 2013 | WO |
| WO2014085719 | Jun 2014 | WO |
| WO2014143842 | Sep 2014 | WO |
| WO2014144151 | Sep 2014 | WO |
| WO2015049783 | Apr 2015 | WO |
| WO2015066278 | May 2015 | WO |
| WO2015127085 | Aug 2015 | WO |
| WO2016064863 | Apr 2016 | WO |
| WO2018157172 | Aug 2018 | WO |
| WO2018157175 | Aug 2018 | WO |
| WO2019046413 | Mar 2019 | WO |
| WO2019046415 | Mar 2019 | WO |
| WO2019133776 | Jul 2019 | WO |
| WO2019133777 | Jul 2019 | WO |
| WO2019222640 | Nov 2019 | WO |
| WO2020033768 | Feb 2020 | WO |
| 2020115473 | Jun 2020 | WO |
| WO2020142658 | Jul 2020 | WO |
| WO2020148155 | Jul 2020 | WO |
| WO2020150195 | Jul 2020 | WO |
| WO2020232414 | Nov 2020 | WO |
| WO2020232419 | Nov 2020 | WO |
| WO2021087382 | May 2021 | WO |
| WO2021142472 | Jul 2021 | WO |
| 2021154833 | Aug 2021 | WO |
| 2021245667 | Dec 2021 | WO |
| WO2021258025 | Dec 2021 | WO |
| 2022123567 | Jun 2022 | WO |
| 2022123574 | Jun 2022 | WO |
| 2022123580 | Jun 2022 | WO |
| 2022192757 | Sep 2022 | WO |
| 2023018992 | Feb 2023 | WO |
| 2023049873 | Mar 2023 | WO |
| 2023092103 | May 2023 | WO |
| Entry |
|---|
| Arjunan Thesis—Plasma Produced Reactive Oxygen and Nitrogen Species in Angiogenesis—May 2011—Krishna Priya Arjunan. |
| Arora et al., Nitric Oxide Regulation of Bacterial Biofilms, Biochemistry, vol. 54, pp. 3717-3728, May 21, 2015. |
| Barraud et al., Involvement of Nitric Oxide n Biofilm Dispersal of Pseudomonas Aeruginosa, Journal of Bacteriology, vol. 188, No. 21, pp. 7344-7353, Nov. 2006. |
| Bellerophon, “Dose Escalation Study to Assess the Safety and Efficacy of Pulsed iNO in Subjects With Pulmonary Fibrosis”, Aug. 30, 2017, https://clinicaltrials.gov/ct2/show/NCT03267108. |
| Bentur et al., Pilot Study to Test Inhaled Nitric Oxide in Cystic Fibrosis Patients with Refactory Mycobacterium abscessus Lung Infection, Journal of Cystic Fibrosis, vol. 19, pp. 225-231, May 23, 2019. |
| Birkeland, K., “On the Oxidation of Atmospheric Nitrogen in Electric Arc”, A Paper read before the Faraday Society on Monday, Jul. 2, 1906, Published on Jan. 1, 1906. |
| Bogdonovski et al., Anti-Mycobacterial Activity of High-Dose Nitric Oxide Against Mycobacterium abscessus In Vitro, National Institutes of Health Poster, Jul. 8, 2018. |
| Charles, et al., “SiO2 Deposition from Oxygen/Silane Pulsed Helicon Diffusion Plasmas” Applied Physics Letters, vol. 67, No. 1, pp. 40-42, Jul. 3, 1995. |
| Deppisch et al., Gaseous Nitric Oxide to Treat Antibiotic Resistant Bacterial and Fungal Lung Infections in Patients with Cystic Fibrosis: A Phase I Clinical Study, Infection, vol. 44, pp. 513-520, Feb. 9, 2016. |
| Dobrynin et al. “Direct and Controllable Nitric Oxide into Biological Media and Living Cells by a Pin-to-Hole Spark Discharge (PHD) Plasma” Journal of Physics D: Applied Physics, vol. 44, pp. 1-10, Jan. 28, 2011. |
| Donohoe et al., “Production of O3, NO, and N2O in a Pulsed Discharge at 1 Atm”, Ind. Eng. Chem., Fundam., vol. 16, No. 2, pp. 208-215, May 1977. |
| Encyclopaedia Britannica, “Soda Lime” published Nov. 12, 2018, https://www.britannica.com/science/soda-lime. |
| Feigerle, C., et al., “Multiphoton Ionization of Vibrationally Hot Nitric Oxide Produced in a Pulsed Supersonic Glow Discharge”, Journal of Chemical Physics, vol. 90, Issue 6, pp. 2900-2908, Mar. 15, 1989. |
| Fowler, “Exercise Intolerance in Pulmonary Arterial Hypertension”, Pulmonary Medicine, vol. 2012, Article ID 39204, 11 pages, (2012). |
| Habib, Bassam Hanna, “A Simple Model of Spark Gap Discharge Phase”, Eng. & Tech. Journal, vol. 31, Part (A), No. 9, pp. 1692-1704, 2013. |
| Hanning et al., “Pulse Oximetry: A Practical Review”, British Medical Journal, vol. 311, pp. 367-370, Aug. 5, 1995. |
| Heli, Study on the Removal of Byproduct Nitrogen Dioxide from the Mixture of Inhaled Nitric Oxide Produced by Pulsed Arc Discharge, Thesis for Degree of Master of Engineering, Huazhong University of Science & Technology, China, Apr. 2006, 78 pages (Includes English Language Translation of Title Page and Abstract). |
| Higenbottam et al., “The Direct and Indirect Action of Inhaled Agents on the Lung and Its Circulation: Lessons from Clinical Science,” Environmental Health Perspectives, vol. 109, Supplement 4, pp. 559-562, Aug. 2001. |
| Howlin et al., Low-Dose Nitric Oxide as Targeted Anti-Biolfim Adjunctive Therapy to Treat Chronic Pseudomonas Aeruoginosa Infection in Cystic Fibrosis, Molecular Therapy, vol. 25, No. 9, pp. 2104-2116, Sep. 2017. |
| Hu, Hui et al., “Study on Production of Nitric Monoxide for Respiratory Distress by Pulsed Discharge”, Proceedings of the CSEE, vol. 23, No. 2, Jan. 2005. |
| Hu, Hui et al., “Study on Pulse Arc Discharge Conditions on Production of Nitric Oxide for Medical Application”, High Voltage Apparatus, Issue 3, Mar. 2005. |
| Hu et al., “Study on Production of Inhaled Nitric Oxide for Medical Applications by Pulsed Discharge”, IEEE Transactions on Plasma Science, vol. 35, No. 3, pp. 619-625, Jun. 2007. |
| Hu, Hui et al., “The Effect of Flow Distribution on the Concentration of NO Produced by Pulsed Arc Discharge”, Plasma Science and Technology, vol. 9, No. 6, pp. 766-769, Dec. 2007. |
| Hu, Hui, Research on the Production of Nitric Oxide by Pulsed Arc Discharge and the Curing of Respiratory Distress Instrument, Dissertation for Degree of Doctor of Philosophy in Engineering, Huazhong University of Science and Technology, China, Apr. 2005, 128 pages (Includes English Language Translation of Title Page and Abstract). |
| Intersurgical Complete Respiratory Systems, Carbon Dioxide Absorbents Catalogue, www.intersurgical.com/distributors, Issue 5, Oct. 17, 2021. |
| Johns Hopkins University—“American Chemical Journal vol. XXXV”—No. 4, Reports Chapter, pp. 358-368, Apr. 1906. |
| Keshav, Saurabh. “Using Plasmas for High-speed Flow Control and Combustion Control” Diss. The Ohio State University, 2008. |
| Kornev, J., et al., “Generation of Active Oxidant Species by Pulsed Dielectric Barrier Discharge in Water-Air Mixtures”, Ozone: Science & Engineering, vol. 28, Issue 4, pp. 207-215, Jul. 2006. |
| Kuo, Spencer P. “Air Plasma for Medical Applications” J. Biomedical Science and Engineering, vol. 5, pp. 481-495. |
| Li, Z. et al., “Development of Miniature Pulsed Power Generator,” 2005 IEEE Pulsed Power Conference Monterey, CA, pp. 1053-1056, Jul. 2005. |
| Li et al., Production of Medically Useful Nitric Monoxide Using AC Arc Discharge, Nitric Oxide, vol. 73, pp. 89-95, Feb. 28, 2018. |
| Lorente L., “Respiratory Filters and Ventilator-Associated Pneumonia: Composition, Efficacy Tests and Advantages and Disadvantages”, Humidification in the Intensive Care Unit, pp. 171-177, Springer, Berlin, Heidelberg 2012. |
| Matsuo, K. et al., “Nitric Oxide Generated by Atmospheric Pressure Air Microplasma,” 2009 IEEE Pulsed Power Conference, Washington, DC, Jun. 28-Jul. 2, 2009, pp. 999-1003, Jan. 19, 2010. |
| McMullin et al., The Antimicrobial Effect of Nitric Oxide on the Bacteria That Cause Nosocomial Pneumonia in Mechanically Ventilated Patients in the Intensive Care Unit, Respiratory Care, vol. 50, No. 11, pp. 1451-1456, Nov. 2005. |
| Miller et al., Gaseous Nitric Oxide Bactericidal Activity Retained During Intermittent High-Dose Short Duration Exposure, Nitric Oxide, vol. 20, Issue 1, pp. 16-23, Feb. 2009. |
| Miller et al., Inhaled Nitric Oxide Decreases the Bacterial Load in a Rat Model of Pseudomonas Aeruginosa Pneumonia, Journal of Cystic Fibrosis, vol. 12, pp. 817-820, Mar. 6, 2013. |
| Miller et al., Nitric Oxide is a Potential Antimicrobial Against Slow and Fast Growing Mycobacteria, Online Abstracts Issue, American Journal Respiratory Care Medicine, vol. 193, A7498, May 18, 2016. |
| Miller et al., A Phase I Clinical Study of Inhaled Nitric Oxide in Healthy Adults, Journal of Cystic Fibrosis, vol. 11, pp. 324-331, Apr. 18, 2012. |
| Mok et al. “Application of Positive Pulsed Corona Discharge to Removal of SO2 and NOx,” Proceedings, ICESP VII, Sep. 20-25, 1998, Kyongiu, Korea. |
| Namihira et al., Production of Nitric Oxide Using Pulsed Discharges for a Medical Application, IEEE Transactions on Plasma Science, vol. 28, No. 1, pp. 109-114, Feb. 2000. |
| Namihara et al., “Production of NO Using Pulsed Arc Discharges and Its Medical Applications”, Journal of Plasma and Fusion Research, vol. 79, No. 1 pp. 35-38, Jun. 25, 2002. |
| Namihira et al., “Production of Nitric Monoxide in Dry Air Using Pulsed Discharge,” Digest of Technical Papers. 12th IEEE International Pulsed Power Conference. (Cat. No. 99CH36358), Monterey, CA, pp. 1313-1316 vol. 2, Aug. 6, 2002. |
| Namihira et al., Production of Nitric Oxide Using a Pulsed Arc Discharge, IEEE Transactions on Plasma Science, vol. 30, No. 5, pp. 1993-1998, Oct. 2002. |
| Namihira et al., “Temperature and Nitric Oxide Generation in a Pulsed Arc Discharge Plasma” Plasma Science and Technology, vol. 9, No. 6, pp. 747-751, Dec. 2007. |
| Navarro-Gonzalez et al., “The Physical Mechanism of Nitric Oxide Formation in Simulated Lightning” Geophysical Research Letters, vol. 28, No. 20, pp. 3867-3870, Oct. 15, 2001. |
| Olivier et al., Treatment of Refractory Mycobacterium abscessus Lung Infection with Inhaled Intermittent Nitric Oxide, Poster, Jul. 8, 2018. |
| Overzet, et al. “Why and How to Pulse a Plasma”—slide show presentation, Oct. 1997. |
| Patil et al., Plasma Assisted Nitrogen Oxide Production from Air, AiChE Journal, vol. 64, Issue 2, Aug. 14, 2017. |
| Pawlat et al., Evaluation of Oxidative Species in Gaseous, Plasma Chemistry and Plasma Processing, vol. 39, pp. 627-642, Mar. 28, 2019. |
| Pontiga, F., et al., “Nitrogen Oxides Generation Induced by Negative Corona Discharge in N2+02 Mixtures,” 2006 IEEE Conference on Electrical Insulation and Dielectric Phenomena, Kansas City, MO, pp. 264-267, Oct. 2006. |
| Sakai, et al., “A Compact Nitric Oxide Supply for Medical Application,” 2007 16th IEEE International Pulsed Power Conference, Albuquerque, NM, 752-755, Oct. 14, 2008. |
| Sakai et al., “Nitric Oxide Generator Based on Pulsed Arc Discharge”Acta Physica Polonica A, vol. 115, No. 6, pp. 1104-1106, Jun. 2009. |
| Schilz, “Treatment of Pulmonary Hypertension Related to Disorders of Hypoxia” Advances in Pulmonary Hypertension, vol. 4, No. 2, pp. 14-22, May 2005. |
| Takaki, et al., “Resistance of Pulsed Arc Discharge in Air and SF/sub 6”, Pulse Power Plasma Science, vol. 2, pp. 1758-1761, Jun. 2001. |
| Tal et al., Nitric Oxide Inhalations in Bronchiolitis: A Pilot, Randomized, Double-Blinded, Controlled Trial, Pediatric Pulmonology, vol. 53, Issue 1, pp. 95-102, Jan. 2018. |
| Tsukahara et al., “Gas-Phase Oxidation of Nitric Oxide: Chemical Kinetics and Rate Constant,” Nitric Oxide: Biology and Chemistry, vol. 3, No. 3, pp. 191-198, Jun. 1999. |
| Wang et al., Gliding Arc Plasma for CO2 Conversion, Chemical Engineering Journal, vol. 330, pp. 11-25, 2017. |
| Yaacoby-Bianu et al., Compassionate Nitric Oxide Adjuvant Treatment of Persistent Mycobacterium Infection in Cystic Fibrosis Patients, The Pediatric Infectious Disease Journal, vol. 37, No. 4, Apr. 2018. |
| Yu, et al., “Detection and Removal of Impurities in Nitric Oxide Generated from Air by Pulsed Electrical Discharge”, Nitric Oxide, vol. 60, pp. 16-23, Nov. 30, 2016. |
| Yu, et al. “Development of a Portable Mini-Generator to Safely Produce Nitric Oxide for the Treatment of Infants with Pulmonary Hypertension”, Nitric Oxide, vol. 75, pp. 7-76, May 1, 2018. |
| International Search Report in PCT/US2021/038149 dated Nov. 12, 2021. |
| U.S. Appl. No. 15/907,241 2018/0243527 U.S. Pat. No. 10,286,176, filed Feb. 27, 2018 Aug. 30, 2018 May 14, 2019, Systems and Methods for Generating Nitric Oxide. |
| U.S. Appl. No. 15/907,258 2018/0243528 U.S. Pat. No. 10,328,228, filed Feb. 27, 2018 Aug. 30, 2018 Jun. 25, 2019, Systems and Methods for Ambulatory Generation of Nitric Oxide. |
| U.S. Appl. No. 16/363,505 2019/0217042 U.S. Pat. No. 10,576,329, filed Mar. 25, 2019 Jul. 18, 2019 Mar. 3, 2020, Systems and Methods for Ambulatory Generation of Nitric Oxide. |
| U.S. Appl. No. 16/388,464 2019/0314596 U.S. Pat. No. 10,532,176, filed Apr. 18, 2019 Oct. 17, 2019 Jan. 14, 2020, Systems and Methods for Generating Nitric Oxide. |
| U.S. Appl. No. 16/697,498 2020/0094011 U.S. Pat. No. 10,695,523, filed Nov. 27, 2019 Mar. 26, 2020 Jun. 30, 2020, Systems and Methods for Generating Nitric Oxide. |
| U.S. Appl. No. 16/724,233 2020/0139072 U.S. Pat. No. 11,033,705, filed Dec. 21, 2019 May 7, 2020 Jun. 15, 2021, Systems and Methods for Ambulatory Generation of Nitric Oxide. |
| U.S. Appl. No. 16/875,971 2020/0361772, filed May 15, 2020 Nov. 19, 2020, Systems and Methods for Generating Nitric Oxide. |
| U.S. Appl. No. 16/875,687 2020/0360649 U.S. Pat. No 11,045,620, filed May 15, 2020 Nov. 19, 2020 Jun. 29, 2021, Electrodes for Nitric Oxide Generation. |
| U.S. Appl. No. 16/875,914 2020/0361773, filed May 15, 2020 Nov. 19, 2020, Architectures for Production of Nitric Oxide. |
| U.S. Appl. No. 17/146,468 2021-0214222, filed Jan. 11, 2021, Systems and Methods for Nitric Oxide Generation with Humidity Control. |
| U.S. Appl. No. 16/909,722 2020/0390994 U.S. Pat. No. 10,946,163, filed Jun. 23, 2020 Dec. 17, 2020 Mar. 16, 2021, Systems and Methods for Generating Nitric Oxide. |
| U.S. Appl. No. 17/197,911 2021/0268221 U.S. Pat. No. 11,376,390, filed Mar. 10, 2021 Sep. 2, 2021 Jul. 5, 2022, Systems and Methods for Generating Nitric Oxide. |
| U.S. Appl. No. 17/332,915 2022/0047837, filed May 27, 2021 Feb. 17, 2022, Systems and Methods for Ambulatory Generation of Nitric Oxide. |
| U.S. Appl. No. 17/331,793 2021/0353898, filed May 27, 2021 Nov. 18, 2021, Electrodes for Nitric Oxide Generation. |
| U.S. Appl. No. 17/352,225 2021/0395905, filed Jun. 18, 2021 Dec. 23, 2021, Systems and Methods for Preventing and Treating Infections with Nitric Oxide. |
| U.S. Appl. No. 17/503,223 2022/0135406, filed Oct. 15, 2021 May 5, 2022, Nitric Oxide Generation Process Controls. |
| U.S. Appl. No. 17/670,655 2022/0162070, filed Feb. 14, 2022 May 26, 2022, Systems and Methods for Generating Nitric Oxide. |
| U.S. Appl. No. 17/693,279, filed Mar. 11, 2022, Systems and Methods for Nitric Oxide Generation and Delivery. |
| U.S. Appl. No. 17/703,497 2022/0211967, filed Mar. 23, 2022 Jul. 7, 2022, Systems and Methods for Ambulatory Generation of Nitric Oxide. |
| U.S. Appl. No. 17/773,369, filed Apr. 29, 2022, Systems and Methods for Increasing Nitrogen Monoxide Concentration and Removing Nitrogen Dioxide from a Gas Stream. |
| U.S. Appl. No. 17/855,592, filed Jun. 30, 2022, Systems and Methods for Generating Nitric Oxide. |
| Lovich et al., “Generation of Purified Nitric Oxide from Liquid N204 for the Treatment of Pulmonary Hypertension in Hypoxemic Swine”, Nitric Oxide vol. 37, pp. 66-77. |
| Number | Date | Country | |
|---|---|---|---|
| 20220298653 A1 | Sep 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63194145 | May 2021 | US | |
| 63159981 | Mar 2021 | US | |
| 63040982 | Jun 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 17352225 | Jun 2021 | US |
| Child | 17837416 | US |
